Embecta (EMBC) 10-K 22 Dec 22 2022 FY Annual report Financial data

Cover Page

Cover Page - USD ($)	12 Months Ended
	Sep. 30, 2022	Nov. 30, 2022	Mar. 31, 2022
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Sep. 30, 2022
Current Fiscal Year End Date	--09-30
Document Transition Report	false
Entity File Number	001-41186
Entity Registrant Name	EMBECTA CORP.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	87-1583942
Entity Address, Address Line One	300 Kimball Drive, Suite 300
Entity Address, City or Town	Parsippany
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07054
City Area Code	201
Local Phone Number	847-6880
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	EMBC
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 0
Entity Common Stock, Shares Outstanding		57,074,073
Documents Incorporated by Reference	The information required by Items 10, 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K is incorporated by reference to the Registrant’s definitive proxy statement for its 2023 Annual Meeting of Stockholders (the “2023 Proxy Statement”), which will be filed pursuant to Regulation 14A with the United States Securities and Exchange Commission (“SEC”) within 120 days after the end of the fiscal year to which this report relates.
Entity Central Index Key	0001872789
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Amendment Flag	false

Audit Information

Audit Information	12 Months Ended
	Sep. 30, 2022
Audit Information [Abstract]
Auditor Name	ERNST & YOUNG LLP
Auditor Location	New York, New York
Auditor Firm ID	42

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) $ in Millions		12 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Revenues		$ 1,129.5	$ 1,165.3	$ 1,085.5
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]		Product [Member]	Product [Member]	Product [Member]
Cost of products sold	[1]	$ 354.6	$ 364.9	$ 322.9
Cost, Product and Service [Extensible Enumeration]		Product [Member]	Product [Member]	Product [Member]
Gross Profit		$ 774.9	$ 800.4	$ 762.6
Operating expenses:
Selling and administrative expense		294.8	240.3	214.7
Research and development expense		66.9	63.3	61.4
Impairment expense		58.9	0	0
Other operating expenses		44.7	4.8	0
Total Operating Expenses		465.3	308.4	276.1
Operating Income		309.6	492	486.5
Interest expense, net		(46.2)	0	0
Other income (expense), net		(6.8)	2.9	(0.7)
Income Before Income Taxes		256.6	494.9	485.8
Income tax provision		33	80.1	58.2
Net Income		$ 223.6	$ 414.8	$ 427.6
Net Income per common share:
Basic (in dollars per share)		$ 3.92	$ 7.28	$ 7.50
Diluted (in dollars per share)		$ 3.89	$ 7.28	$ 7.50
[1]For periods prior to the Separation, this income statement line includes cost of products sold from related party inventory purchases. Refer to Note 4 for further detail.

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Statement of Comprehensive Income [Abstract]
Net Income	$ 223.6	$ 414.8	$ 427.6
Other Comprehensive Income (Loss), net of tax
Foreign currency translation adjustments	(64.2)	(8.9)	16.4
Other Comprehensive Income (Loss), net of tax	(64.2)	(8.9)	16.4
Comprehensive Income	$ 159.4	$ 405.9	$ 444

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2022	Sep. 30, 2021
Current Assets
Cash and cash equivalents	$ 330.9	$ 0
Trade receivables, net	22.2	150.6
Inventories:
Materials	23.4	13.1
Work in process	5.6	21
Finished products	93.8	83.9
Inventories	122.8	118
Amounts due from Becton, Dickinson and Company	110.9	0
Prepaid expenses and other	77.9	23.2
Total Current Assets	664.7	291.8
Property, Plant and Equipment, Net	301.6	450.9
Goodwill and Other Intangible Assets	24.6	33.9
Deferred Income Taxes and Other Assets	95.5	11.4
Total Assets	1,086.4	788
Current Liabilities
Accounts payable	41.4	54.2
Accrued expenses	104.3	81.6
Amounts due to Becton, Dickinson and Company	66.5	0
Salaries, wages and related items	48.5	28.2
Current debt obligations	9.5	0
Current finance lease liabilities	3.6	0
Income taxes	27.2	0
Total Current Liabilities	301	164
Deferred Income Taxes and Other Liabilities	46.1	29.7
Long-Term Debt	1,598.1	0
Non Current Finance Lease Liabilities	32.6	0
Commitments and Contingencies
Embecta Corp. Equity
Common stock, $0.01 par value Authorized - 250,000,000 Issued and outstanding - 57,055,327	0.6
Additional paid-in capital	10
Accumulated deficit	(577.1)
Net Investment from Becton, Dickinson and Company		864.8
Accumulated other comprehensive loss	(324.9)	(270.5)
Total Equity	(891.4)	594.3
Total Liabilities and Equity	$ 1,086.4	$ 788

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical)	Sep. 30, 2022 $ / shares shares
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share) | $ / shares	$ 0.01
Common stock, authorized (in shares)	250,000,000
Common stock, issued (in shares)	57,055,327
Common stock, outstanding (in shares)	57,055,327

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) $ in Millions	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Net Investment from Becton, Dickinson and Company	Accumulated Other Comprehensive (Loss) Income
Beginning balance at Sep. 30, 2019	$ 577.1				$ 855.1	$ (278)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to Diabetes Care Business/ Embecta Corp.	427.6				427.6
Other comprehensive loss, net of taxes	16.4					16.4
Net transfers to Becton, Dickinson and Company	(448.9)				(448.9)
Net consideration paid to Becton, Dickinson, and Company in connection with Separation	0
Ending balance at Sep. 30, 2020	572.2				833.8	(261.6)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to Diabetes Care Business/ Embecta Corp.	414.8				414.8
Other comprehensive loss, net of taxes	(8.9)					(8.9)
Net transfers to Becton, Dickinson and Company	(383.8)				(383.8)
Net consideration paid to Becton, Dickinson, and Company in connection with Separation	0
Ending balance at Sep. 30, 2021	594.3				864.8	(270.5)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to Diabetes Care Business/ Embecta Corp.	223.6			$ 45.2	178.4
Other comprehensive loss, net of taxes	(64.2)					(64.2)
Net transfers to Becton, Dickinson and Company	(1,712.9)
Net transfers to Becton, Dickinson and Company including Separation adjustments	(380.5)				(390.3)	9.8
Common dividends ($0.15 per share)	(8.6)			(8.6)
Net consideration paid to Becton, Dickinson, and Company in connection with Separation	(1,266)				(1,266)
Issuance of common stock in connection with the Separation and reclassification of Net Investment from Becton, Dickinson and Company (in shares)		57,012,925
Issuance of common stock in connection with the Separation and reclassification of Net Investment from Becton, Dickinson and Company	0	$ 0.6		(613.7)	$ 613.1
Stock-based compensation plans	$ 10		$ 10
Issuance of shares related to share-based compensation plans (in shares)		42,402
Ending balance (in shares) at Sep. 30, 2022	57,055,327	57,055,327
Ending balance at Sep. 30, 2022	$ (891.4)	$ 0.6	$ 10	$ (577.1)		$ (324.9)

Consolidated Statements of Eq_2

Consolidated Statements of Equity (Parenthetical)	12 Months Ended
	Sep. 30, 2022 $ / shares
Statement of Stockholders' Equity [Abstract]
Dividend declared (in dollars per share)	$ 0.15

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Operating Activities
Net Income	$ 223,600,000	$ 414,800,000	$ 427,600,000
Adjustments to net income to derive net cash provided by operating activities:
Depreciation and amortization	31,700,000	38,300,000	38,300,000
Amortization of debt issuance costs	3,200,000	0	0
Impairment of property, plant and equipment	58,900,000	13,800,000	0
Stock-based compensation	18,700,000	12,800,000	12,700,000
Net periodic pension benefit and other postretirement costs	10,200,000	9,400,000	9,400,000
Deferred income taxes	(26,500,000)	(2,800,000)	(2,200,000)
Change in operating assets and liabilities:
Trade receivables, net	122,700,000	(31,800,000)	(2,400,000)
Inventories	(23,400,000)	(18,000,000)	3,500,000
Due from/due to Becton, Dickinson and Company	(47,000,000)	0	0
Prepaid expenses and other	(44,000,000)	(11,500,000)	15,400,000
Accounts payable, accrued expenses and other current liabilities	73,300,000	30,800,000	(3,800,000)
Income and other net taxes payable	10,300,000	0	0
Other assets, net	500,000	500,000	0
Net Cash Provided by Operating Activities	412,200,000	456,300,000	498,500,000
Investing Activities
Capital expenditures	(23,600,000)	(36,800,000)	(41,900,000)
Acquisition of intangible assets	(400,000)	(2,400,000)	0
Net Cash Used for Investing Activities	(24,000,000)	(39,200,000)	(41,900,000)
Financing Activities
Proceeds from the issuance of long-term debt	1,450,000,000	0	0
Payments on long-term debt	(4,800,000)	0	0
Payment of long-term debt issuance costs	(33,300,000)	0	0
Payment of revolving credit facility fees	(5,600,000)	0	0
Payments on finance lease	(1,800,000)	0	0
Dividend payments	(8,600,000)	0	0
Net consideration paid to Becton, Dickinson and Company in connection with the Separation	(1,266,000,000)	0	0
Net transfers to Becton, Dickinson and Company	(177,900,000)	(417,100,000)	(456,600,000)
Net Cash Used for Financing Activities	(48,000,000)	(417,100,000)	(456,600,000)
Effect of exchange rate changes on cash and cash equivalents	(9,300,000)	0	0
Net Change in Cash and cash equivalents	330,900,000	0	0
Opening Cash and cash equivalents	0	0	0
Closing Cash and cash equivalents	$ 330,900,000	$ 0	$ 0

Background

Background	12 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background	Background Embecta Corp. ("Embecta" or the "Company") is a leading global medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. The Company has a broad portfolio of marketed products, including a variety of pen needles, syringes and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The Company primarily sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients. On April 1, 2022 (the "Separation Date"), Embecta and Becton, Dickinson and Company ("BD") entered into a Separation and Distribution Agreement (the "Separation and Distribution Agreement"). Pursuant to the Separation and Distribution Agreement, BD agreed to spin off its diabetes care business ("Diabetes Care Business") into Embecta, a new, publicly traded company (the "Separation"). The Separation occurred by means of a pro-rata distribution (the "Distribution") of all of Embecta’s issued and outstanding shares of common stock on the basis of one share of Embecta common stock, par value $0.01 per share, for every five shares of BD common stock, par value $1.00 per share, held as of the close of business on March 22, 2022, the record date for the distribution. Embecta is now a standalone publicly traded company and, on April 1, 2022, regular-way trading of Embecta common stock commenced on the Nasdaq Global Select Market under the ticker symbol "EMBC". In connection with the Separation, BD and Embecta entered into various agreements to provide a framework for the relationship between BD and Embecta after the Separation, including, but not limited to, a separation and distribution agreement, a transition services agreement, a tax matters agreement, an employee matters agreement, a cannula supply agreement, contract manufacturing agreements, an intellectual property matters agreement, a logistics services agreement, distribution agreements, factoring and receivables agreements, local support and service agreements and other transaction documents.

Basis of Presentation

Basis of Presentation	12 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation On April 1, 2022, the Company became a standalone publicly traded company, and its financial statements are now presented on a consolidated basis. Prior to the Separation on April 1, 2022, the Company’s historical combined financial statements were prepared on a standalone basis and were derived from BD's consolidated financial statements and accounting records. The financial statements for all periods presented, including the historical results of the Company prior to April 1, 2022, are now referred to as "Consolidated Financial Statements", and have been prepared pursuant to the rules and regulations for reporting on Form 10-K. Periods Prior to Separation Prior to the Separation, the Company was referred to as the Diabetes Care Business. The assets, liabilities, revenue and expenses of the Diabetes Care Business were reflected in the combined financial statements on a historical cost basis, as included in the consolidated financial statements of BD, using the historical accounting policies applied by BD. The Consolidated Financial Statements did not purport to reflect what the Company’s results of operations, comprehensive income, financial position, equity or cash flows would have been had the Company operated as a standalone public company during the periods presented. The Diabetes Care Business had historically functioned together with the other businesses controlled by BD. Accordingly, the Diabetes Care Business relied on BD’s corporate and other support functions for its business. Therefore, for the period prior to the Separation, certain corporate and shared costs were allocated to the Diabetes Care Business based on a specific identification basis or, when specific identification was not practicable, a proportional cost allocation method, including: i. expenses related to BD support functions, including expenses for facilities, executive oversight, treasury, finance, legal, human resources, shared services, compliance, procurement, information technology and other corporate functions. ii. certain manufacturing and supply costs incurred by BD, including facility management, distribution, logistics, planning and global quality. iii. certain costs incurred by BD’s Medication Delivery Solutions organizational unit in relation to selling and marketing activities, and related administrative support functions. iv. certain costs incurred by BD for activities related to device research and development, as well as medical and regulatory affairs. v. stock-based compensation expenses (see Note 9). vi. certain compensation expenses maintained on a centralized basis such as certain employee benefit expenses. Management believes these cost allocations were a reasonable reflection of the utilization of services provided to, or the benefit derived by, the Diabetes Care Business during the period prior to the Separation, though the allocations may not be indicative of the actual costs that would have been incurred had the Diabetes Care Business operated as a standalone public company. Actual costs that may have been incurred if the Diabetes Care Business had been a standalone company would depend on a number of factors, including the chosen organizational structure, whether functions were outsourced or performed by Diabetes Care Business employees, and strategic decisions made in areas such as manufacturing, selling and marketing, research and development, information technology and infrastructure. BD utilized a centralized approach to cash management and the financing of its operations. Cash generated by the Diabetes Care Business was routinely transferred into accounts managed by BD’s centralized treasury function and cash disbursements related to operations prior to the Separation were funded as needed by BD. Balances held by the Diabetes Care Business with BD for cash transfers and loans were reflected as Due to related party prior to the Separation. All other cash and cash equivalents and related transfers between BD and the Diabetes Care Business were generally held centrally through accounts controlled and maintained by BD and were not specifically identifiable to the Diabetes Care Business. Accordingly, such balances were accounted for through Net Investment from Becton, Dickinson and Company . BD’s third-party debt and related interest expense were not attributed to the Diabetes Care Business because the business was not the legal obligor of the debt and the borrowings were not specifically identifiable to the business. For the Diabetes Care Business, transactions with BD affiliates were included in the Consolidated Statements of Income and related balances were reflected as Due to related party , Due from related party or Related Party Loans Payable . Other balances between the Diabetes Care Business and BD were considered to be effectively settled in the Consolidated Financial Statements at the time the transactions were recorded. As the separate legal entities that made up the Diabetes Care Business were not historically held by a single legal entity, Net Investment from Becton, Dickinson and Company was shown in lieu of stockholders’ equity in these Consolidated Financial Statements. Net Investment from Becton, Dickinson and Company represented BD’s interest in the recorded assets of the Diabetes Care Business and the cumulative investment by BD through the date of the Separation, inclusive of operating results. Income tax expense and tax balances in the Consolidated Financial Statements were calculated on a separate tax return basis. The separate tax return method applies the accounting guidance for income taxes to the standalone financial statements as if we were a separate taxpayer and a standalone enterprise. Management believes the assumptions supporting the allocation and presentation of income taxes on a separate return basis are reasonable. The provision for income taxes for the period prior to the Separation was calculated by applying an estimated effective income tax rate for the full year to ordinary income adjusted by the tax impact of discrete items. As of the Separation Date Certain assets and liabilities, including patents and unrecognized tax benefits that were included in the Consolidated Balance Sheet prior to the Separation, have been retained by BD post-Separation and therefore were transferred to BD through Net Investment from Becton, Dickinson and Company in the Company's Consolidated Financial Statements. In connection with the Separation, additional pension assets, deferred tax assets, other compensation obligations, and certain other assets and liabilities were transferred to the Company through Net Investment from Becton, Dickinson and Company , and the Company recorded these in the Consolidated Balance Sheet. As part of the Separation, Net Investment from Becton, Dickinson and Company was reclassified as Common Stock and Accumulated Deficit . Periods Post Separation Following the Separation, certain functions continue to be provided by BD under the Transition Services Agreements or are being performed using Embecta’s own resources or third-party service providers. Additionally, under manufacturing and supply agreements, the Company manufactures certain products for BD, or its applicable affiliate and BD manufactures certain products for the Company. The Company incurred certain costs in its establishment as a standalone public company and expects to incur ongoing additional costs associated with operating as an independent, publicly traded company. All intercompany transactions and accounts within Embecta have been eliminated. Certain reclassifications were made to conform the prior period Consolidated Financial Statements to the current period presentation.

Summary of Accounting Policies

Summary of Accounting Policies	12 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Accounting Policies	Summary of Accounting Policies Revenue Recognition The Company recognizes revenue from product sales and considers performance obligations satisfied when the customer obtains control of the product, which is generally upon shipment or delivery, depending on the delivery terms specified in the sales agreement. When arrangements include multiple performance obligations, the total transaction price of the contract is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised goods or services underlying each performance obligation. The point in time upon which shipment or delivery occurs is the most faithful depiction of when control of the goods transfers to the customer. Variable consideration such as rebates, sales discounts, and sales returns are estimated and treated as a reduction of revenue in the same period the related revenue is recognized. These estimates are based on contractual terms, historical practices and current trends, and are adjusted as new information becomes available. Revenues exclude any taxes that the Company collects from customers and remits to tax authorities. Additional disclosures regarding the Company’s accounting for revenue recognition are provided in Note 7. Cash Equivalents Cash equivalents are comprised of certain highly liquid investments with original maturities of three months or less. Trade Receivables The Company grants credit to customers in the normal course of business and the resulting trade receivables are stated at their net realizable value. The allowance for doubtful accounts represents the Company’s estimate of probable credit losses relating to trade receivables and is determined based on historical experience, current conditions, reasonable and supportable forecasts and other specific account data. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectible. Inventories Inventories are stated at the lower of approximate cost or net realizable value determined on the first-in, first-out basis. Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation. Depreciation is principally provided on the straight-line basis over estimated useful lives, which range from 20 to 45 years for buildings, 4 to 13 years for machinery and equipment and 1 to 20 years for leasehold improvements. Depreciation expense was $31.0 million in 2022, $37.2 million in 2021, and $36.5 million in 2020. Property, plant and equipment are periodically reviewed when impairment indicators are present to assess recoverability or a decision has been made to abandon efforts associated with construction in progress assets. Recoverability is determined by comparing the carrying values of the assets or asset groups to the undiscounted cash flows to be generated from the use and eventual disposition of such assets or asset groups. If the asset’s or asset group’s carrying value exceeds such undiscounted cash flows, the assets or asset groups are not recoverable and an impairment loss is recognized based on the amount by which the carrying value of the asset or asset group exceeds its calculated fair value. Capitalized Interest The interest cost on capital projects is capitalized and included in the cost of the project. Capitalization commences with the first expenditure for the project and continues until the project is substantially complete and ready for its intended use. When no debt is incurred specifically for a project, interest is capitalized on project expenditures using the weighted average cost of the Company's outstanding borrowings. For the year ended September 30, 2022, the Company capitalized $5.2 million of interest expense into Property, Plant and Equipment, Net . Advertising Costs Advertising costs are expensed as incurred and included in S elling and administrative expense . The Company recorded advertising costs of $11.6 million, $9.3 million, and $8.2 million in 2022, 2021 and 2020, respectively. Goodwill and Other Intangible Assets Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. The Company has one reporting unit. Goodwill is evaluated for impairment as of July 1 each year, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that fair value is less than carrying value. If the Company concludes it is more likely than not that fair value is less than carrying value, a quantitative fair value test is performed. If carrying value is greater than fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill). We completed the annual goodwill impairment test as of July 1, 2022 and concluded that no impairment to goodwill was necessary as the fair value of the Company's one reporting unit was significantly in excess of the carrying value. No goodwill impairments were identified during the years ended September 30, 2021, or 2020, and no accumulated impairment losses are recorded. Amortized intangible assets primarily consist of patents and customer relationships. Patents are generally amortized over 20 years using the straight-line method. Customer relationship assets are generally amortized over periods ranging from 10 to 15 years, using the straight-line method. Other intangibles with finite useful lives are amortized over periods principally ranging from 1 to 40 years, using the straight-line method. Finite-lived intangible assets are periodically reviewed when impairment indicators are present to assess recoverability from future operations using undiscounted cash flows. The carrying values of these finite-lived assets are compared to the undiscounted cash flows they are expected to generate and an impairment loss is recognized in operating results to the extent any finite-lived intangible asset’s carrying value exceeds its calculated fair value. Foreign Currency Translation Generally, foreign subsidiaries’ functional currency is the local currency of operations and the net assets of foreign operations are translated into United States dollars using current exchange rates. The United States dollar results that arise from such translation are included in Accumulated other comprehensive loss . Shipping and Handling Costs The Company considers its shipping and handling costs to be contract fulfillment costs and records them within selling and administrative expense. Shipping and handling costs were $27.4 million, $13.6 million, and $12.4 million in 2022, 2021, and 2020, respectively. Contingencies The Company establishes accruals for future losses which are both probable and can be reasonably estimated (and in the case of environmental matters, without considering possible third-party recoveries). Additional disclosures regarding the Company’s accounting for contingencies are provided in Note 6. Stock-Based Compensation Prior to the Separation, certain of the Company’s employees historically participated in BD’s stock-based compensation plans. Stock-based compensation expense was either allocated to the Company based on a proportionate cost allocation method or recorded based on specific identification. Effective April 1, 2022, the Company established the 2022 Employee and Director Equity Based Compensation Plan (the "Plan"). The Plan provides for the grant of various types of awards, including restricted stock unit awards, stock appreciation rights, stock options, performance-based awards and cash awards. Under the Plan, the exercise price of awards, if any, is set on the grant date and generally may not be less than the fair market value per share on that date. The Company measures stock-based compensation for equity awards at fair value on the date of grant and records stock-based compensation as a charge to earnings net of the estimated impact of forfeited awards. Accordingly, the Company recognizes stock-based compensation cost only for those stock-based awards that are estimated to ultimately vest over their requisite service period, based on the vesting provisions of the individual grants. The cumulative effect on current and prior periods of a change in the estimated forfeiture rate is recognized as compensation cost in earnings in the period of the change (see Note 9). Benefit Plans Prior to the Separation, the defined benefit plans in which the Company participated related primarily to plans sponsored by BD and for which other businesses of BD also participate (the "Shared Plans"). The Company accounted for the Shared Plans as multiemployer plans and therefore the related assets and liabilities were not reflected in the Consolidated Balance Sheets. For such periods prior to the Separation, the Consolidated Statements of Income reflect a proportional allocation of net periodic benefit cost for the Shared Plans associated with the Company. The Company's participation in the defined pension and postretirement benefit plans sponsored by BD concluded upon the completion of the Separation on April 1, 2022. At Separation, Embecta became the plan sponsor for certain non-United States defined benefit pension plans (see Note 17). Research and Development Research and development costs are expensed as incurred. Income Taxes Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement and tax basis of assets and liabilities at the applicable tax rates. We maintain valuation allowances where it is more likely than not that all or a portion of a deferred tax asset will not be realized. Changes in valuation allowances are included in the tax provision in the period of change. In determining whether a valuation allowance is warranted, we evaluate factors such as prior earnings history, expected future earnings, carryback and carryforward periods, and tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset. From time to time, the Company engages in transactions in which tax consequences may be subject to uncertainty. The Company conducts business and files tax returns in numerous jurisdictions based on its interpretation of tax laws and regulations. In evaluating the Company’s tax provision, the Company establishes a reserve for uncertain tax positions unless such positions are determined to be more likely than not of being sustained upon examination based on the technical merits. The Company’s policy is to recognize, when applicable, interest and penalties on uncertain tax positions as part of income tax expense. While the Company believes it has identified all reasonable exposures and the reserve it has established is appropriate under the circumstances, it is possible that additional exposures exist and that exposures may be settled at amounts different than the amounts reserved. It is also possible that changes in facts and circumstances could cause the Company to either materially increase or reduce the carrying amount of its tax reserve. The Tax Cuts and Jobs Act was enacted on December 22, 2017 and introduced an additional U.S. tax on certain non-US. Subsidiaries’ earnings which are referred to as Global Intangible Low Taxed Income (“GILTI”) . The Company has elected to treat GILTI as a period cost. Prior to the Separation, our operations were included in the tax returns of BD. Income taxes as presented in the Consolidated Financial Statements attribute current and deferred income tax assets and liabilities of BD to us in a manner that is systematic, rational, and consistent with the asset and liability method prescribed by the accounting guidance for income taxes. Our income tax provision prior to the Separation was prepared using the separate return method. The separate return method applies the accounting guidance for income taxes to the standalone financial statements as if we were a separate taxpayer and a standalone enterprise. We believe the assumptions supporting the allocation and presentation of income taxes on a separate return basis are reasonable. Additional disclosures regarding our accounting for income taxes are provided in Note 13. Segment Data The Company operates and reports its financial information as one segment. In making this determination, the Company (i) determines its Chief Operating Decision Maker (“CODM”), (ii) identifies and analyzes potential business components, (iii) identifies its operating segments and (iv) determines whether there are multiple operating segments requiring presentation as reportable segments. The Company’s decision to report as one segment is based upon the following: (1) its internal organizational structure; (2) the manner in which its operations are managed; and (3) the criteria used by the Company’s President, its CODM, to evaluate performance of the Company’s business and allocate resources and capital. Fair Value Measurements A fair value hierarchy is applied to prioritize inputs used in measuring fair value. The three levels of inputs used to measure fair value are detailed below. Additional disclosures regarding the Company’s fair value measurements are provided in Note 14. Level 1—Inputs to the valuation methodology which represent unadjusted quoted prices in active markets for identical assets and liabilities. Level 2—Inputs to the valuation methodology which include: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability. Level 3—Inputs to the valuation methodology which are unobservable and significant to the fair value measurement. Leases We determine whether an arrangement contains a lease at inception. If a lease is identified in an arrangement, we recognize a right-of-use asset and liability in our Consolidated Balance Sheets and determine whether the lease should be classified as a finance or operating lease. We do not recognize assets or liabilities for leases with lease terms of less than 12 months. A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to Embecta by the end of the lease term, (ii) we hold an option to purchase the leased asset that we are reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases. Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the implicit rate is not readily determinable, the Company utilizes its incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease. For lease arrangements that are recognized on the Company’s Consolidated Balance Sheets, the right-of-use asset and lease liability is initially measured at the commencement date based upon the present value of the lease payments due under the lease. These payments represent the combination of the fixed lease and fixed non-lease components that are due under the arrangement. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, we reflect the option in the lease term if it is reasonably certain we will exercise the option. Finance leases are recorded in Property, Plant and Equipment, Ne t, Current finance lease liabilities , and Non Current Finance Lease Liabilities and operating leases are recorded in Deferred Income Taxes and Other Assets , Accrued expenses , and Deferred Income Taxes and Other Liabilities in our Consolidated Balance Sheets. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions. These estimates or assumptions affect reported assets, liabilities, revenues and expenses, including determining the allocation of shared costs and expenses from BD, depreciable and amortizable lives, sales returns and allowances, rebate accruals, inventory reserves and taxes on income as reflected in the Consolidated Financial Statements. Actual results could differ from these estimates. Net Investment from Becton, Dickinson and Company — Net investment from Becton, Dickinson and Company represented BD’s interest in the recorded assets of the Company and the cumulative investment by BD in the Company through the date of the Separation, inclusive of operating results and the net effect of the transactions with and allocations from BD. See Notes 2 and 4 for additional information. Supplemental Disclosures Of Cash Flow Information Cash paid for interest related to debt during the year ended September 30, 2022 was $38.9 million. The Company did not have any debt outstanding during the years ended September 30, 2021 and 2020. Cash paid for income taxes, net of refunds, for the year ended September 30, 2022 was $15.6 million. For the years ended September 30, 2021 and 2020, the Company's current tax liabilities computed under the separate return method are considered to be effectively settled at the time the transaction is recorded, with the offset recorded against Net investment from Becton, Dickinson and Company . Recently Adopted Accounting Standards In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12, Income Taxes - Simplifying the Accounting for Income Taxes (Topic 740). The updated guidance simplifies the accounting for income taxes by removing certain exceptions in Topic 740 and clarifying and amending existing guidance. The amendments are effective for fiscal years beginning after December 15, 2020, with early adoption permitted. The Company adopted the provisions of this new accounting standard at the beginning of fiscal 2022 and adoption did not have a material impact on its consolidated financial statements. Recently Issued Accounting Standards Not Yet Adopted In October 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2021-08, "Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts

Third Party Arrangements and Re

Third Party Arrangements and Related Party Disclosures	12 Months Ended
	Sep. 30, 2022
Third Party and Related Party Transactions [Abstract]
Third Party Arrangements and Related Party Disclosures	Third Party Arrangements and Related Party Disclosures Pursuant to the Separation, BD ceased to be a related party to Embecta and accordingly, no related party transactions or balances are reported subsequent to April 1, 2022. In connection with the Separation, the Company entered into the Separation and Distribution Agreement, which contains provisions that, among other things, relate to (i) assets, liabilities and contracts to be transferred, assumed and assigned to each of Embecta and BD (including certain deferred assets and liabilities) as part of the Separation, (ii) cross-indemnities principally designed to place financial responsibility for the obligations and liabilities of Embecta's business with Embecta and financial responsibility for the obligations and liabilities of BD’s remaining businesses with BD, (iii) procedures with respect to claims subject to indemnification and related matters, (iv) the allocation among Embecta and BD of rights and obligations under existing insurance policies with respect to occurrences prior to completion of the Separation, as well as the right to proceeds and the obligation to incur certain deductibles under certain insurance policies, and (v) procedures governing Embecta’s and BD’s obligations and allocations of liabilities with respect to ongoing litigation matters that may implicate each of BD’s business and Embecta’s business. Agreements that Embecta entered into with BD that govern aspects of Embecta's relationship with BD following the Separation include, but are not limited to: • Transition Services Agreements ("TSA") - Pursuant to the TSA, Embecta and BD and their respective affiliates provide each other, on an interim, transitional basis, various services, including, but not limited to, information technology, human resources, procurement, quality and regulatory affairs, medical affairs, tax and treasury services. The agreed-upon charges for such services are generally intended to allow the servicing party to charge a price comprised of out-of-pocket costs and expenses and a predetermined profit in the form of a mark-up of such out-of-pocket costs and expenses. The services will terminate no later than 24 months following the Separation. The service recipient may terminate any services by giving prior written notice to the provider of such services and paying any applicable wind-down charges. • Trade Receivables Factoring Agreements - Embecta and BD entered into trade receivables factoring agreements (the "Factoring Agreements"), under which Embecta transfers certain net trade receivable assets to BD, and pays a service fee calculated as 0.1% of annual revenues related to countries subject to the Factoring Agreements in exchange for the services provided by BD. Per the terms of the Factoring Agreements, the Company and its relevant subsidiaries sell receivables to the corresponding BD subsidiary in the same jurisdiction and such BD subsidiary collects the receivables from Company's customers. The BD subsidiary assumes the credit risk in respect of the receivables, and accordingly deducts a factoring fee from the purchase price of such receivables. Accordingly, Embecta accounts for the transfer as sales of trade receivables by recognizing an increase to Cash and cash equivalents and a decrease to Trade Receivables, net in the Consolidated Balance Sheets when proceeds from the transactions are received. The transfers are presented in the Consolidated Statements of Cash Flows as operating activities and the related service fee is presented as a component of Other income (expense), net in the Consolidated Statements of Income. • Distribution Agreements - Embecta and BD entered into distribution agreements for certain territories, principally in the Asia Pacific Region and Latin America, whereby a subsidiary of BD is appointed as a distributor of Embecta or its relevant subsidiaries to support certain commercial operations of the diabetes care business on a transitional basis in these regions for a maximum of two years. The distribution agreements will each continue until either (1) certain governmental approvals needed to distribute products in the defined territory are obtained and order-to-cash processes and other services of the Company for such territory are migrated to an alternative commercial arrangement between the parties or (2) the applicable services are transitioned to a third-party distributor or independently performed by Embecta, but in any event no longer than the maximum term of two years. Embecta shall pay BD a return of 1.5% to 2.0% of net revenue for each territory. • Cannula Supply Agreement - Embecta and BD entered into a cannula supply agreement whereby BD sells to Embecta cannulas for incorporation into Embecta's existing syringes and pen needles, safety syringes and safety pen needles, and insulin patch pump, pen needles and safety pen needle currently under development. BD retains ownership of all cannula technology, cannula production activities and the intellectual property rights therein. Embecta is limited to a maximum number of cannulas that it can purchase under the cannula supply agreement, which will be an absolute upper limit of cannulas per year and yearly limits that vary with annual demand. The cannula supply agreement is terminable by Embecta without cause by providing at least 36 months’ written notice; however, such termination can be effective no earlier than five years from the Separation. The cannula supply agreement will be terminable by BD without cause by providing at least 36 months’ written notice; however, such termination can be effective no earlier than ten years from the Separation. However, in the event of a change of control of Embecta, BD has the right to terminate the cannula supply agreement in its sole discretion. The cannula supply agreement will also terminate automatically, subject to a 36-month wind-down period, if Embecta’s yearly forecast is below the required minimum purchase amount, and the parties have other customary termination rights for material breach or bankruptcy of the other party. • Tax Matters Agreement - Pursuant to the tax matters agreement, Embecta agreed to certain covenants that contain restrictions intended to preserve the tax-free status of the distribution and certain related transactions. Embecta may take certain actions prohibited by these covenants only if Embecta obtains and provides to BD an opinion from a United States tax counsel or accountant of recognized national standing, in either case satisfactory to BD, to the effect that such action would not jeopardize the tax-free status of the distribution and certain related transactions, or if Embecta obtains prior written consent of BD. Embecta is barred from taking any action, or failing to take any action, where such action or failure to act adversely affects or could reasonably be expected to adversely affect the tax-free status of the distribution and certain related transactions or result in certain other taxes to BD, for all relevant time periods. In addition, during the period ending two years after the Separation, these covenants include specific restrictions on Embecta’s (i) discontinuing the active conduct of Embecta’s trade or business; (ii) issuance or sale of stock or other securities (including securities convertible into Embecta stock, but excluding certain compensatory arrangements); (iii) liquidating, merging, or consolidating with any other person; (iv) amending Embecta’s certificate of incorporation (or other organizational documents) or taking any other action, whether through a stockholder vote or otherwise, affecting the voting rights of Embecta common stock; (v) sales of assets outside the ordinary course of business; and (vi) entering into any other corporate transaction which would cause Embecta to undergo a 50% or greater change in its stock ownership. • Logistics Services Agreement - Embecta and BD entered into a logistics services agreement whereby BD provides Embecta with certain order-to-cash and logistics services to support certain commercial operations for a maximum term of two years. Embecta will pay BD (i) reimbursable costs, including all shipping costs, selling costs, general administration costs, costs of goods, research and development services costs, and other income and expenses related solely to the diabetes care business, that are incurred by BD directly, as allocated costs or as costs payable to a third party and (ii) a monthly administrative fee of 1.0% of net revenue. • Other agreements that Embecta entered into with BD include, but are not limited to, the employee matters agreement ("EMA"), an intellectual property matters agreement, local support services agreements, certain other manufacturing arrangements and a process services agreement and lease agreement for a manufacturing facility located in Holdrege, Nebraska. See Note - 16 for more information on the lease agreement for Holdrege. The amount due from BD under the above agreements was $110.9 million at September 30, 2022 and is reflected in Amounts due from Becton, Dickinson and Company . The amount due to BD under these agreements was $66.5 million at September 30, 2022 and is included in Amounts due to Becton, Dickinson and Company . Prior to the Separation, the Company did not operate as a standalone business and the Consolidated Financial Statements were derived from the consolidated financial statements and accounting records of BD. The following disclosure summarizes activity between the Company and BD up to the Separation, including the affiliates of BD that were not part of the Separation. For the years ended September 30, 2022, 2021 and 2020, cost of products sold from related party inventory purchases were $28.0 million, $40.6 million and $43.4 million, respectively. Corporate and Medical Segment Allocations from BD BD provided significant corporate, finance, human resources, information technology, facilities, and legal services, among others (collectively, “General Corporate Expenses”) to the Company. Some of these services continue to be provided by BD to the Company on a temporary basis under the Transition Services Agreement. For purposes of these Consolidated Financial Statements for the periods prior to the Separation, the General Corporate Expenses have been allocated to the Company. The allocations of General Corporate Expenses are reflected in the Consolidated Statements of Income as follows: Year ended September 30, 2022 2021 2020 Cost of products sold $ 2.3 $ 13.0 $ 9.2 Selling and administrative expense 47.9 98.3 80.2 Research and development expense 3.5 5.2 5.4 Other (income) expense, net (0.6) (1.3) 0.5 Total General Corporate Expenses $ 53.1 $ 115.2 $ 95.3 These expenses were allocated to the Company on a pro rata basis of global and regional revenues, headcount, research and development spend and other drivers. Management believes the assumptions underlying the Consolidated Financial Statements, including the assumptions regarding allocating General Corporate Expenses from BD, are reasonable. Nevertheless, the Consolidated Financial Statements for periods prior to the Separation may not include all of the actual expenses that would have been incurred and may not reflect the Company’s Consolidated results of operations, financial position and cash flows had it been a standalone public company during the periods presented. Actual costs that would have been incurred if the Company had been a standalone public company would depend on multiple factors, including organizational structure and strategic decisions made in various areas, including information technology and infrastructure. Related party transactions The following transactions represent activity in the ordinary course of business between the Company and BD prior to the Separation for certain materials for use in production of certain medical products that were not at arm’s length. The following table summarizes related party purchases as follows: Year ended September 30, 2022 2021 2020 Purchases from BD $ 28.0 $ 40.6 $ 43.4 All significant intercompany transactions between the Company and BD prior to the Separation have been included in the Consolidated Financial Statements and are considered to be effectively settled for cash at the time the transaction is recorded. For the period prior to the Separation, the total net effect of the settlement of these intercompany transactions is reflected in the Consolidated Statements of Cash Flows as a financing activity and in the Consolidated Balance Sheets as Net Investment from Becton, Dickinson and Company. Prior to the Separation, net transfers to BD were included within Net Investment from Becton, Dickinson and Company . in the Consolidated Statements of Equity and represent the net effect of transactions between the Company and BD. The following table summarizes the components of the net transfers to BD as follows: Year ended September 30, 2022 2021 2020 Cash pooling and general financing activities (1) $ 255.9 $ 599.5 $ 591.8 Corporate and segment allocations, excluding non-cash stock-based compensation (50.4) (109.9) (90.4) Taxes deemed settled with BD (16.2) (72.5) (44.8) Other Separation related adjustments, net (11.4) — — Net transfers to BD as reflected in the Consolidated Statements of Cash Flows 177.9 417.1 456.6 Share-based compensation expense (8.5) (12.5) (12.7) Pension expense (3.6) (9.4) (9.4) Net Consideration paid to BD in connection with the Separation 1,266.0 — — Related party senior secured notes 197.0 — — Other transfers to (from) BD, net 84.1 (11.4) 14.4 Net transfers to BD $ 1,712.9 $ 383.8 $ 448.9 (1) The nature of activities includes financing activities for capital transfers, cash sweeps and other treasury services. As part of this activity, cash balances were swept to BD on a daily basis under the BD Treasury function and the Company receives capital from BD for its cash needs. Related Party Senior Secured Notes On March 31, 2022, Embecta issued $200.0 million of senior secured notes to BD (the "Related Party Notes"). The Related Party Notes issued to BD were not issued for cash and instead were subject to a debt-for-debt exchange which occurred on April 1, 2022. As of April 1, 2022 t he Related Party Notes were reclassified to Long-Term Debt in the Consolidated Balance Sheets as the Related Party Notes are third party debt for periods post Separation. Refer to Note 11 for further information.

Other Operating Expenses

Other Operating Expenses	12 Months Ended
	Sep. 30, 2022
Other Income and Expenses [Abstract]
Other Operating Expenses	Other Operating Expenses In connection with the Separation further described in Note 1, the Company incurred separation and stand-up costs of approximately $44.7 million and $4.8 million during the years ended September 30, 2022 and 2021, respectively. There were no separation and stand-up costs incurred during the year ended September 30, 2020. The costs incurred primarily relate to accounting, auditing, and legal services, including costs to establish certain stand-alone corporate functions and other costs associated with the abandonment of certain manufacturing production lines.

Contingencies

Contingencies	12 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies The Company is subject to potential liabilities under government regulations and various claims and legal actions that are pending or may be asserted from time-to-time. These matters arise in the ordinary course and conduct of the Company’s business and include, for example, commercial, intellectual property, environmental, securities and employment matters. The Company intends to continue to defend itself vigorously in such matters and when warranted, take legal action against others. Furthermore, the Company regularly assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. An estimated loss contingency is accrued in the Company’s Financial Statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Based on the Company’s assessment, it has adequately accrued an amount for contingent liabilities currently in existence. The Company does not accrue amounts for liabilities that it does not believe are probable. Litigation is inherently unpredictable, and unfavorable resolutions could occur. As a result, assessing contingencies is highly subjective and requires judgment about future events. The amount of ultimate loss may exceed the Company’s current accruals, and it is possible that its cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of one or more of these contingencies.

Revenues

Revenues	12 Months Ended
	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenues	Revenues Measurement of Revenues Payment terms extended to the Company’s customers are based upon commercially reasonable terms for the markets in which the Company’s products are sold. Because the Company generally expects to receive payment within one year or less from when control of a product is transferred to the customer, the Company does not generally adjust its revenues for the effects of a financing component. The Company’s allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of its trade receivables. Such estimated credit losses are determined based on historical loss experiences, customer specific credit risk, and reasonable and supportable forward-looking information, such as country or regional risks that are not captured in the historical loss information. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectible. The allowance for doubtful accounts for trade receivables is not material to the Company’s consolidated financial results. The Company’s gross revenues are subject to a variety of deductions which are recorded in the same period that the underlying revenues are recognized. Such variable consideration includes rebates, sales discounts, and sales returns. Because these deductions represent estimates of the related obligations, judgment is required when determining the impact of these revenue deductions on gross revenues for a reporting period. Rebates provided by the Company are based upon prices determined under the Company’s agreements primarily with its end-user customers. Additional factors considered in the estimate of the Company’s rebate liability include the quantification of inventory that is either in stock at or in transit to the Company’s distributors, as well as the estimated lag time between the sale of product and the payment of corresponding rebates. The Company’s liability attributed to variable consideration at September 30, 2022 and September 30, 2021 was $43.8 million and $71.7 million, respectively. The decrease is primarily attributed to the Factoring Agreements by which certain trade receivables are factored to BD net of variable consideration. Sales deductions recorded as a reduction of gross revenues for the years ended September 30, 2022, 2021 and 2020 were $336.4 million, $298.7 million, and $300.7 million respectively. Disaggregation of Revenues Disaggregation of revenue by geographic region is provided within Note 8. Contract Assets and Liabilities The Company does not have contract liabilities. Contract assets consist of the Company’s right to consideration that is conditional upon its future performance pursuant to private label agreements and are presented within Prepaid expenses and other in the Consolidated Balance Sheets.

Segment and Geographical Data

Segment and Geographical Data	12 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Segment and Geographical Data	Segment and Geographical Data Operating segments are identified as components of an enterprise in which discrete financial information is available for evaluation by the CODM in making decisions regarding assessing business performance and allocating resources and capital. Management has concluded that the Company operates in one segment based upon the information used by the CODM in evaluating the performance of the Company’s business and allocating resources and capital. Disaggregation of Revenues The Company has distribution agreements with regional or national distributors (including wholesalers and medical suppliers) to ensure broad availability of its products as well as a direct sales force in certain countries and regions around the world. In the United States and Canada, the Company utilizes large and small key account managers that call on payers, retailers, wholesalers and institutional customers, and field-based territory managers that call on health care providers and pharmacies. In certain markets within Europe, the Company has dedicated sales representatives and in certain regions of the Middle East and Africa, the Company has distribution agreements. In Greater Asia, the Company has distribution agreements and in China, the Company relies on its own commercial team to support sales execution. In Latin America, the Company maintains distribution agreements and direct sales representatives. The Company disaggregates its revenue by geography as management believes this category best depicts how the nature, amount, and timing of revenues and cash flows are affected by economic factors. Revenues by geographic region are as follows: Year ended September 30, 2022 2021 2020 United States $ 600.3 $ 609.4 $ 563.0 International (1) 529.2 555.9 522.5 Total $ 1,129.5 $ 1,165.3 $ 1,085.5

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation Periods Prior to Separation Prior to the Separation, certain of the Company's employees participated in stock-based compensation plans sponsored by BD. Under these plans BD granted time-vested restricted stock units ("TVUs"), stock appreciation rights ("SARs"), and performance share units ("PSUs") to certain management level employees. Prior to the Separation on April 1, 2022, share-based compensation expense in the Consolidated Statements of Income is representative of those employees who were dedicated to the Diabetes Care Business. Additionally, share-based compensation expense was allocated to the Diabetes Care Business for BD Corporate and Medical Segment employees who were not dedicated solely to the Diabetes Care Business. This stock-based compensation expense was allocated using a proportional cost allocation method and is included as a component of corporate allocations for periods prior to the Separation. The amounts presented for the periods prior to the Separation are not necessarily indicative of future awards and do not necessarily reflect the costs that the Company would have incurred as an independent company. As of Separation Date and Periods Post Separation In connection with the Separation, and in accordance with the EMA, Embecta's employees with outstanding former BD share-based awards received replacement share-based awards under the Plan. The ratio used to convert the BD share-based awards was designed to preserve the aggregate intrinsic value of the award immediately after the Separation when compared to the aggregate intrinsic value of the award immediately prior to Separation. As a result of the award modification, Embecta will incur $6.1 million of incremental stock-based compensation expense. Of this amount, $2.3 million was recognized during the year ended September 30, 2022. $3.8 million will be recognized at a future date over the awards' remaining vesting period. Effective April 1, 2022, Embecta established the Plan. A total of 7,000,000 shares of common stock are authorized under the Plan. The Plan provides for the grant of various types of awards including restricted stock unit ("RSU") awards, SARs, stock options, performance-based awards and other stock-based awards. Under the Plan, the exercise price of awards, if any, is set on the grant date and may not be less than the fair market value per share on that date. Generally SARs have a term of ten years and a three The Company recognizes stock-based compensation cost only for those stock-based awards that are estimated to ultimately vest over their requisite service period, based on the vesting provisions of the individual grants. The cumulative effect on current and prior periods of a change in the estimated forfeiture rate is recognized as compensation cost in earnings in the period of the change. On April 1, 2022, Embecta granted 48,192 potential shares to non-employee directors in the form of RSUs, which vest at the earlier of (i) the first anniversary of the grant date or (ii) the date of the first annual meeting of stockholders, subject to continued service of the recipients. On April 4, 2022 and in connection with the Separation, Embecta granted 860,611 of potential shares to members of the Embecta leadership team as a one-time sign-on equity grant, subject to continued employment, comprised of the following: • 172,787 grants of time-vested RSUs which cliff vest on the third anniversary after grant date; • 528,167 grants of SARs which cliff vest on the third anniversary after grant date and; • 27,653 of TVUs and 132,004 of SARs granted to the Embecta's chief executive officer which vest evenly over three Stock-Based Compensation Expense Total direct and allocated stock-based compensation expense for the years ended September 30, 2022, 2021, and 2020 and the respective income tax benefits recognized by the Company in the Consolidated Statements of Income are as follows: 2022 2021 2020 Cost of products sold $ 2.3 $ 2.7 $ 2.4 Selling and administrative expense 14.6 7.8 7.8 Research and development expense 1.8 2.3 2.2 Total Stock-Based Compensation Expense $ 18.7 $ 12.8 $ 12.4 Tax benefit associated with stock-based compensation costs recognized $ 2.9 $ 2.8 $ 3.0 Stock Appreciation Rights SARs represent the right to receive, upon exercise, shares of common stock having a value equal to the difference between the market price of common stock on the date of exercise and the exercise price on the date of grant. SARs generally vest over a period of three In connection with the SARs granted during 2022, the Company used the BSM to determine the fair value of the SARs as of the grant date. In applying this model, the Company uses both historical data and current market data to estimate the fair value of its SARs. The expected dividend yield is based on forecasted patterns of dividend payments. The risk-free interest rate is based on the rate at grant date of zero-coupon United States Treasury Notes with a term equal to the expected term of the SAR. Expected volatility is estimated using historical volatility. Due to the lack of trading history of Embecta's stock at the time of valuation efforts, the historical component of expected volatility is based on historical monthly price changes of the peer group within the industry. BD's historical data for Embecta employees was used to estimate equity award exercise and employee termination behavior within the valuation model. The expected term represents the amount of time that SARs granted are expected to be outstanding based on historical and forecasted exercise behavior. The weighted average fair value of SARs was determined using the following assumptions: 2022 Risk-free interest rate 2.5 % Expected volatility 37.8 % Expected dividend yield 2.9 % Expected life 6.5 Fair value per SAR $ 9.38 A summary of SARs outstanding as of September 30, 2022 and changes since the Separation Date are as follows: SARs (in thousands) Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Balance at April 1 1,379.8 $ 27.70 Granted 660.2 31.40 Exercised* (9.0) 13.66 Forfeited, canceled or expired (114.3) $ 28.64 Balance at September 30 1,916.7 $ 28.98 8.7 $ 1.4 Vested and expected to vest at September 30 1,824.0 $ 28.96 8.7 $ 1.4 Exercisable at September 30 230.6 $ 25.71 6.2 $ 0.8 *The amounts exercised include shares withheld for taxes that are not formally issued to the market. SARs with an intrinsic value of $0.1 million and grant date fair value of $6.1 million were exercised since the Separation Date. Time-Vested Restricted Stock Units Time vested restricted stock unit awards vest on a graded basis over a period of three years. The related stock-based compensation expense is recorded over the requisite service period, which is the vesting period or is based on retirement eligibility. The fair value of all time vested restricted stock units is based on the market value of the Company’s stock on the date of grant. A summary of time-vested restricted stock units outstanding as of September 30, 2022 and changes since the Separation Date are as follows: Stock Units (in thousands) Weighted Average Grant Date Fair Value Nonvested at April 1 847.0 $ 27.41 Granted 248.6 31.23 Distributed* (58.5) 27.41 Forfeited, canceled or expired (59.6) 28.03 Nonvested at September 30 977.5 $ 28.34 Expected to vest at September 30 930.8 $ 28.34 *The amounts distributed include shares withheld for taxes that are not formally issued to the market. The weighted average grant date fair value of time restricted stock units granted since the Separation Date is $31.23 and the total fair value of time vested stock units vested since the Separation Date is $1.6 million. At September 30, 2022, the weighted average remaining vesting term of time vested restricted stock units is 1.7 years. Unrecognized Compensation Expense and Other Stock Plans

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	12 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets consisted of: Weighted Average Amortization Period (Years) September 30, 2022 September 30, 2021 Amortized intangible assets Patents – gross 13.0 $ 9.4 $ 20.8 Less: accumulated amortization (3.9) (6.5) Patents – net $ 5.5 $ 14.3 Customer Relationships and Other – gross 6.9 $ 5.2 $ 5.4 Less: accumulated amortization (1.8) (1.4) Customer Relationships and Other – net $ 3.4 $ 4.0 Total amortized intangible assets $ 8.9 $ 18.3 Goodwill 15.7 15.6 Total Goodwill and Other Intangible Assets $ 24.6 $ 33.9 Intangible asset amortization expense was $0.7 million for the year ended September 30, 2022 and $0.3 million for the years ended September 30, 2021 and 2020, respectively. The estimated intangible asset amortization expense for each of the fiscal years ended September 30, 2023 through 2027 is expected to approximate $1.1 million per year and $3.4 million for years subsequent thereafter.

Long-Term Debt

Long-Term Debt	12 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt 5.00% Senior Secured Notes due 2030 On February 10, 2022 Embecta issued $500.0 million aggregate principal amount of 5.00% senior secured notes due February 15, 2030 (the “5.00% Notes”). Interest payments on the 5.00% Notes are due semi-annually in February and August until maturity . 6.75% Senior Secured Notes due 2030 On March 31, 2022, Embecta issued $200.0 million of 6.75% Related Party Notes at a discount of $3.0 million. The Related Party Notes issued to BD were not issued for cash and instead were subject to a debt-for-debt exchange which occurred on April 1, 2022. As such, the issuance of the Related Party Notes is a non-cash financing activity and is not presented in the Consolidated Statements of Cash Flows for the year ended September 30, 2022. On April 1, 2022, BD transferred the Related Party Notes with a notional value of $200.0 million issued by Embecta to Morgan Stanley in exchange for certain notes of BD that were purchased by Morgan Stanley pursuant to a tender offer. Morgan Stanley then sold the senior secured notes to qualified institutional buyers in the United States pursuant to Rule 144A under the Securities Act of 1933, as amended. As of April 1, 2022, the 6.75% senior secured notes (the "6.75% Notes") became third party debt of Embecta. Interest payments on the 6.75% Notes are due semi-annually in February and August until maturity. The 6.75% Notes will mature on February 15, 2030. Credit Agreement On March 31, 2022, Embecta entered into a credit agreement (the “Credit Agreement”), providing for: • a Term Loan B Facility (the "Term Loan") in the amount of $950.0 million, with a seven -year term that matures in March 2029. The interest rate is 300 basis points over the secured overnight financing rate (“SOFR”), with a 0.50% SOFR floor. The Term Loan was issued at a discount of 0.50%. Principal and interest payments on the Term Loan commenced on June 30, 2022. Such quarterly principal payments are calculated as 0.25% of the initial principal amount, with the remaining balance payable upon maturity; and • a Revolving Credit Facility (the "Revolving Credit Facility") in an aggregate principal amount of up to $500.0 million, with a five -year term that matures in 2027. Borrowings under the Revolving Credit Facility bear interest, at Embecta’s option, at an annual rate equal to (a) in the case of loans denominated in United States dollars (i) the SOFR or (ii) the alternate base rate or (b) in the case of loans denominated in Euros, the EURIBOR rate, in each case plus an applicable margin specified in the credit agreement. A commitment fee applies to the unused portion of the Revolving Credit Facility, equal to 0.25% per annum. As of September 30, 2022, no amount has been drawn on the Revolving Credit Facility. The credit agreement and the senior secured notes are secured by substantially all assets of Embecta and each subsidiary guarantor, subject to certain exceptions. The Credit Agreement and the indentures for the 5.00% and 6.75% Notes contain customary financial covenants, including a total net leverage ratio covenant, which measures the ratio of (i) consolidated total net debt to (ii) consolidated earnings before interest, taxes, depreciation and amortization, and subject to other adjustments, must meet certain defined limits which are tested on a quarterly basis in accordance with the terms of the Credit Agreement and the 5.00% and 6.75% Notes. In addition, the Credit Agreement contains covenants that will limit, among other things, Embecta’s ability to prepay, redeem or repurchase its subordinated and junior lien debt, incur additional debt, make acquisitions, merge with other entities, pay dividends or distributions, redeem or repurchase equity interests, and create or become subject to liens. The following is a summary of Embecta's total debt outstanding as of September 30, 2022: Term Loan $ 945.3 5.00% Notes 500.0 6.75% Notes 200.0 Total principal debt issued $ 1,645.3 Less: current debt obligations (9.5) Less: debt issuance costs and discounts (37.7) Long-term debt $ 1,598.1 The debt issuance costs on the Term Loan, 5.00% Notes, 6.75% Notes and the discount on the Term Loan are reported in the Consolidated Balance Sheets as a reduction of debt and are amortized as a component of Interest expense, net over the term of the related debt using the effective interest method. The schedule of principal payments required on long-term debt for the next five fiscal years and thereafter is as follows: 2023 $ 9.5 2024 $ 9.5 2025 $ 9.5 2026 $ 9.5 2027 $ 9.5 Thereafter $ 1,597.8 The estimated fair value of long-term debt (including current portion) at September 30, 2022 was $1,531.3 million compared with a carrying value (which includes a reduction for amortized debt issuance costs and discounts) of $1,607.6 million. Fair value was estimated using inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability and would be considered Level 2 in the fair value hierarchy.

Earnings per Share

Earnings per Share	12 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Earnings per Share	Earnings per Share On April 1, 2022, the date of the Separation, 57,012,925 shares of Embecta's common stock, par value $0.01 per share, were distributed to BD shareholders of record as of March 22, 2022, the record date of the transaction. This share amount is utilized for the calculation of basic and diluted earnings per share for all periods presented prior to the Separation. In connection with the Separation, and in accordance with the EMA, Embecta's employees with outstanding former BD share-based awards received replacement share-based awards under the Plan. The ratio used to convert the BD share-based awards was designed to preserve the aggregate intrinsic value of the award immediately after the Separation when compared to the aggregate intrinsic value of the award immediately prior to the Separation (see Note 9 for additional details). The calculation of basic and diluted earnings per common share for the years ended September 30, 2022, 2021 and 2020 were as follows: ($ in millions and shares in thousands, except per share amounts) 2022 2021 2020 Net Income attributable to Embecta $ 223.6 $ 414.8 $ 427.6 Basic weighted average number of shares outstanding 57,024 57,013 57,013 Stock awards and equity units (share equivalent) 437 — — Diluted weighted average shares outstanding 57,461 57,013 57,013 Earnings per common share - Basic $ 3.92 $ 7.28 $ 7.50 Earnings per common share - Diluted $ 3.89 $ 7.28 $ 7.50 For periods prior to the Separation, it is assumed that there were no dilutive equity instruments as there were no equity awards of Embecta outstanding prior to the Separation. For periods subsequent to the Separation, diluted earnings per share is computed by giving effect to all potentially dilutive stock awards that are outstanding. For 2022, 1.8 million of dilutive share equivalents issuable under stock-based compensation plans were excluded from the diluted shares outstanding calculation because the result would have been antidilutive.

Income Taxes

Income Taxes	12 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income (Loss) Before Income Taxe s The components of Income Before Income Taxes for the years ended September 30 consisted of: 2022 2021 2020 Domestic $ (29.1) $ 87.5 $ 73.8 Foreign 285.7 407.4 412.0 Income before income taxes $ 256.6 $ 494.9 $ 485.8 Provision for Income Taxes The provision (benefit) for income taxes for the years ended September 30 consisted of: 2022 2021 2020 Current: Federal $ 20.4 $ 19.2 $ 1.0 State 3.4 4.3 3.7 Foreign 35.7 59.4 55.7 $ 59.5 $ 82.9 $ 60.4 Deferred: Federal $ (31.1) $ (1.3) $ (2.7) State (4.6) (0.3) — Foreign 9.2 (1.2) 0.5 $ (26.5) $ (2.8) $ (2.2) Income tax provision $ 33.0 $ 80.1 $ 58.2 The Company's income tax provision for the first half of 2022 and the years ended September 30, 2021 and 2020 were prepared using a separate return method. The separate return method applies the accounting guidance for income taxes to the standalone financial statements as if the Company was a separate taxpayer and a standalone enterprise. The Company believes the assumptions supporting the allocation and presentation of income taxes on a separate return basis are reasonable. For a portion of 2022 and all periods prior to the Separation, the Company’s domestic and foreign operations are included in BD’s domestic consolidated and foreign tax returns, and payments to all tax authorities are made by BD on the Company’s behalf. The Company files its own foreign tax return and makes its own foreign tax payments in Ireland. The Company’s current tax liabilities computed under the separate return method are considered to be effectively settled in the consolidated financial statements at the time the transaction is recorded, with the offset recorded against Net parent investment. Tax Rate Reconciliation A reconciliation of federal statutory tax rate to the Company's effective income tax rate was as follows: 2022 2021 2020 Federal statutory tax rate 21.0 % 21.0 % 21.0 % State and local income taxes, net of federal tax benefit (0.8) 0.7 0.6 Foreign income tax at rates other than 21% (7.0) (6.1) (6.7) US tax on foreign earnings 0.2 0.5 0.5 Taxes on unremitted foreign earnings 3.2 — — Tax reserves (1.8) 0.5 (3.0) Tax credits (0.7) (0.4) (0.4) Nontaxable items (1.1) — — Other, net (0.1) — — Effective income tax rate 12.9 % 16.2 % 12.0 % The decrease in the Company's effective income tax rate from 2022 as compared to 2021 was primarily due to the change in geographical mix of earnings and favorable unrecognized tax benefits recorded in 2022; partially offset by tax expense that have been provided on undistributed earnings of foreign subsidiaries. The increase in the Company's effective income tax rate from 2021 as compared to 2020 was primarily impacted by favorable unrecognized tax benefits recorded in 2020. Deferred Income Taxes Deferred income taxes at September 30 consisted of: 2022 2021 Deferred tax assets: Compensation and benefits $ 8.6 $ 2.1 Accruals and reserves 10.3 5.3 Intangibles 26.2 — Property, plant and equipment 19.0 — Capitalized research and development expenses 7.0 — Leases 9.7 — Tax loss and credit carryforwards 0.5 0.3 Other 5.4 1.6 Gross deferred tax assets before valuation allowance $ 86.7 $ 9.3 Valuation allowance $ (10.4) $ (0.3) Total deferred tax assets $ 76.3 $ 9.0 Deferred tax liabilities: Property, plant and equipment $ — $ (8.3) Taxes on unremitted foreign earnings (8.2) — Right of use asset (9.5) — Other — (2.0) Total deferred tax liabilities $ (17.7) $ (10.3) Net deferred tax assets (liabilities) (i) $ 58.6 $ (1.3) i. Net deferred tax assets are included in Deferred Income Taxes and Other Assets and net deferred tax liabilities are included in Deferred Income Taxes and Other Liabilities in the Consolidated Balance Sheets. Deferred tax assets and liabilities are netted in the Consolidated Balance Sheets by separate tax jurisdictions. As of September 30, 2022, the Company has recorded deferred taxes on undistributed earnings of foreign subsidiaries. As of September 30, 2021 the Company has not provided deferred taxes on undistributed earnings in 2021. The determination of the amount of the unrecognized deferred tax liability in 2021 related to the undistributed earnings is not practicable because of the complexities associated with its hypothetical calculation. The Company has recorded valuation allowances of $10.4 million for certain foreign deferred tax assets due to uncertainty that exists regarding future realizability. Unrecognized Tax Benefits The table below summarizes the gross amounts of unrecognized tax benefits without regard to reduction in tax liabilities or additions to deferred tax assets and liabilities if such unrecognized tax benefits were settled. The Company believes it is reasonably possible that the amount of unrecognized tax benefits will change due to one or more of the following events in the next twelve months: expiring statutes, audit activity, and tax payments in matters that are the subject of controversy in various taxing jurisdictions in which the Company operates. 2022 2021 2020 Balance at October 1 $ 16.0 $ 14.5 $ 28.4 Increase due to current year tax positions 1.0 1.3 0.8 Increase due to prior year tax positions — 0.3 0.1 Decrease due to prior year tax positions (6.7) — (14.8) Decrease due to settlements with tax authorities — (0.1) — Decrease due to lapse of statute of limitations (4.6) — — Balance at September 30 $ 5.7 $ 16.0 $ 14.5 Unrecognized tax benefits including interest and penalties that would affect the effective tax rate if recognized $ 7.2 $ 20.0 $ 17.4 For a portion of 2022 and all periods prior to the Separation, the Company’s domestic and foreign operations were included in BD’s domestic consolidated and foreign tax returns, with the exception of Ireland. The Company conducts business and files tax returns in numerous countries and currently has no tax audits in progress for the period after the Separation. The following were included for the years ended September 30 as a component of Income tax provision in the Consolidated Statements of Income. 2022 2021 2020 Interest and penalties associated with unrecognized tax benefits $ 1.5 $ 4.0 $ 2.9

Financial Instruments and Fair

Financial Instruments and Fair Value Measurements	12 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Financial Instruments and Fair Value Measurements	Financial Instruments and Fair Value Measurements The following reconciles Cash and cash equivalents reported within the Consolidated Balance Sheets as of September 30, 2022 and September 30, 2021, to the total amounts shown in the Consolidated Statements of Cash Flows: September 30, 2022 September 30, 2021 Cash and cash equivalents $ 330.9 $ — Cash and cash equivalents includes cash held in money market funds and other cash equivalents. All cash and cash equivalents are Level 1 in the fair value hierarchy. Foreign Currency Risks and Related Strategies The Company has foreign currency exposures throughout Europe, Greater Asia, Canada and Latin America. Transactional currency exposures that arise from entering into transactions, generally on an intercompany basis, in non-hyperinflationary countries that are denominated in currencies other than the functional currency are mitigated primarily through the use of forward contracts. The notional amounts of the Company’s foreign currency-related derivative instruments were as follows: Hedge Designation September 30, 2022 September 30, 2021 Foreign exchange contracts (a) Undesignated $ 5.1 $ — a. Represent hedges of transactional foreign exchange exposures resulting primarily from intercompany payables and receivables. Gains and losses on these instruments are recognized immediately in Other income (expense), net . These gains and losses are largely offset by gains and losses on the underlying hedged items, as well as the hedging costs associated with the derivative instruments. Gains and losses recognized to date on these instruments were not material to the Company's Consolidated Financial Statements. Nonrecurring Fair Value Measurements Non-financial assets, including property, plant and equipment as well as intangible assets, are measured at fair value when there are indicators of impairment and these assets are recorded at fair value only when an impairment is recognized. These measurements of fair value are generally based upon Level 3 inputs, including values estimated using the income approach. During the year ended September 30, 2022, the Company recorded impairment charges of $58.9 million related to the abandonment of certain manufacturing production lines in the United States that are no longer expected to be completed. These assets were previously included as a component of Construction in progress within Property, Plant and Equipment . The impairment charges are recognized within Impairment expense in the Consolidated Statements of Income. During the year ended September 30, 2021, the Company recorded impairment charges related to certain construction in progress assets related to discontinued projects totaling $13.8 million. The impairment charges were recorded to adjust the carrying amount of the assets to the assets’ fair values, which were estimated through a discounted cash flow model that utilized Level 3 inputs. The impairment charges are recognized within Cost of products sold in the Consolidated Statements of Income. There were no impairment charges incurred during the year ended 2020. Concentration of Credit Risk Historically and prior to the Separation, the Company’s operations formed part of BD’s monitoring of concentrations of credit risk associated with financial institutions for which BD conducted business. As of September 30, 2022, the Company had transferred the majority of its trade receivables to BD under the Factoring Agreements (see Note 4). As a result, the Company is no longer exposed to credit risk associated with those transferred receivables and does not have material credit risk exposure associated with the remaining $22.2 million of trade receivables. Three of the Company’s customers represented at least 10.0% of total gross revenues individually and, in the aggregate, represented approximately 40.1% for the year ended September 30, 2022. Two customers represented at least 10.0% of total revenues individually and, in the aggregate, represented 30.7% and 32.7% of total revenues for the years ended September 30, 2021 and 2020, respectively.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment Property, Plant and Equipment, Net consisted of: As of September 30, 2022 As of September 30, 2021 Land $ 1.4 $ 3.5 Buildings 123.7 120.4 Machinery, equipment and fixtures 505.1 570.8 Leasehold improvements 6.5 6.1 Construction in progress 64.9 190.8 $ 701.6 $ 891.6 Less: accumulated depreciation (400.0) (440.7) Total Property, Plant and Equipment, Net $ 301.6 $ 450.9 During the year ended September 30, 2022, the Company recorded impairment charges of $58.9 million related to the abandonment of certain manufacturing production lines in the United States that are no longer expected to be completed. These assets were previously included as a component of Construction in progress within Property, Plant and Equipment, Net.

Leases

Leases	12 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Leases	Leases Finance Lease Our finance lease assets and liabilities are attributed to our manufacturing site in Holdrege, Nebraska. This lease is classified as a finance lease because the present value of the sum of the lease payments associated with the lease exceeds substantially all of the fair value of the manufacturing site. Holdrege Lease In conjunction with the Separation, the Company entered into a lease agreement with BD pursuant to which the Company would lease approximately 278,000 square feet of manufacturing space and equipment at BD's manufacturing facility in Holdrege, Nebraska for an initial term of 10 years. The Company determined that the manufacturing space and equipment are highly interdependent and interrelated. Consequently, the Company concluded that the manufacturing space and equipment represent a single lease component. This finance lease is recorded in Buildings within Property, Plant and Equipment, Net , Current finance lease liabilities , and Non Current Finance Lease Liabilities . Base rent payments commenced in the third quarter of 2022. The Company has an option to extend the lease term for an additional period of up to five-years. Operating Leases Our operating leases primarily relate to our real estate leases that are not classified as finance leases. Aggregate Lease Information Our leases are included in our Consolidated Balance Sheets as follows: As of September 30, 2022 As of September 30, 2021 Finance Lease Property, Plant, and Equipment, Net $ 35.5 $ — Total Finance Lease Assets $ 35.5 $ — Current finance lease liabilities $ 3.6 $ — Non Current Finance Lease Liabilities 32.6 — Total Finance Lease Liabilities $ 36.2 $ — Weighted-average remaining lease term (years) 14.5 — Weighted-average discount rate 6.8 % — Operating Leases Deferred Income Taxes and Other Assets $ 6.3 $ 3.9 Total Operating Lease Assets $ 6.3 $ 3.9 Accrued expenses $ 2.0 $ 1.1 Deferred Income Taxes and Other Liabilities 4.3 3.0 Total Operating Lease Liabilities $ 6.3 $ 4.1 Weighted-average remaining lease term (years) 3.2 4.3 Weighted-average discount rate 5.9 % 2.2 % Supplemental cash flow information related to leases for the year ended September 30, 2022 was as follows: September 30, 2022 Right of use assets obtained in exchange for lease liabilities Financing Lease $ 36.7 Operating Leases 2.8 There were no right of use assets obtained in exchange for lease liabilities during the years ended September 30, 2021 and 2020. For the years ended September 30, 2022, 2021, and 2020 lease expense and cash paid for leases were not material. Maturities of our finance and operating lease liabilities as of September 30, 2022 by fiscal year are as follows: Finance Leases Operating Leases Total 2023 3.6 2.3 5.9 2024 3.6 2.1 5.7 2025 3.7 1.2 4.9 2026 3.7 1.0 4.7 2027 3.8 — 3.8 Thereafter 40.1 — 40.1 Total lease payments $ 58.5 $ 6.6 $ 65.1 Less: amount representing interest 22.3 0.3 22.6 Present value of lease liabilities $ 36.2 $ 6.3 $ 42.5
Leases	Leases Finance Lease Our finance lease assets and liabilities are attributed to our manufacturing site in Holdrege, Nebraska. This lease is classified as a finance lease because the present value of the sum of the lease payments associated with the lease exceeds substantially all of the fair value of the manufacturing site. Holdrege Lease In conjunction with the Separation, the Company entered into a lease agreement with BD pursuant to which the Company would lease approximately 278,000 square feet of manufacturing space and equipment at BD's manufacturing facility in Holdrege, Nebraska for an initial term of 10 years. The Company determined that the manufacturing space and equipment are highly interdependent and interrelated. Consequently, the Company concluded that the manufacturing space and equipment represent a single lease component. This finance lease is recorded in Buildings within Property, Plant and Equipment, Net , Current finance lease liabilities , and Non Current Finance Lease Liabilities . Base rent payments commenced in the third quarter of 2022. The Company has an option to extend the lease term for an additional period of up to five-years. Operating Leases Our operating leases primarily relate to our real estate leases that are not classified as finance leases. Aggregate Lease Information Our leases are included in our Consolidated Balance Sheets as follows: As of September 30, 2022 As of September 30, 2021 Finance Lease Property, Plant, and Equipment, Net $ 35.5 $ — Total Finance Lease Assets $ 35.5 $ — Current finance lease liabilities $ 3.6 $ — Non Current Finance Lease Liabilities 32.6 — Total Finance Lease Liabilities $ 36.2 $ — Weighted-average remaining lease term (years) 14.5 — Weighted-average discount rate 6.8 % — Operating Leases Deferred Income Taxes and Other Assets $ 6.3 $ 3.9 Total Operating Lease Assets $ 6.3 $ 3.9 Accrued expenses $ 2.0 $ 1.1 Deferred Income Taxes and Other Liabilities 4.3 3.0 Total Operating Lease Liabilities $ 6.3 $ 4.1 Weighted-average remaining lease term (years) 3.2 4.3 Weighted-average discount rate 5.9 % 2.2 % Supplemental cash flow information related to leases for the year ended September 30, 2022 was as follows: September 30, 2022 Right of use assets obtained in exchange for lease liabilities Financing Lease $ 36.7 Operating Leases 2.8 There were no right of use assets obtained in exchange for lease liabilities during the years ended September 30, 2021 and 2020. For the years ended September 30, 2022, 2021, and 2020 lease expense and cash paid for leases were not material. Maturities of our finance and operating lease liabilities as of September 30, 2022 by fiscal year are as follows: Finance Leases Operating Leases Total 2023 3.6 2.3 5.9 2024 3.6 2.1 5.7 2025 3.7 1.2 4.9 2026 3.7 1.0 4.7 2027 3.8 — 3.8 Thereafter 40.1 — 40.1 Total lease payments $ 58.5 $ 6.6 $ 65.1 Less: amount representing interest 22.3 0.3 22.6 Present value of lease liabilities $ 36.2 $ 6.3 $ 42.5

Benefit Plans

Benefit Plans	12 Months Ended
	Sep. 30, 2022
Retirement Benefits [Abstract]
Benefit Plans	Benefit Plans Defined Benefit Plans Prior to the Separation on April 1, 2022, Embecta participated in BD's non-United States plans. BD has defined benefit pension plans covering eligible employees in certain of its international subsidiaries. The Company participated in BD's benefit plans as though it was a participant in a multi-employer plan with the other businesses of BD. The retirement benefits accounting guidance provides that liabilities beyond any contributions currently due and unpaid are not required to be reported. Accordingly, no assets or liabilities associated with plans where the Company was a participant in a multi-employer plan with the other businesses of BD have been reflected in the Company’s Consolidated Balance Sheets. The Consolidated Statements of Income include expense allocations for these benefits, which were determined using a proportional allocation method. Total benefit plan expense allocated to the Company for the years ended September 30, 2022, 2021 and 2020 was $3.6 million, $9.0 million and $9.0 million, respectively. The Company's participation in the defined pension and postretirement benefit plans sponsored by BD concluded upon the completion of the Separation on April 1, 2022. As of April 1, 2022, Embecta became the plan sponsor for certain global defined benefit pension plans. These Consolidated Financial Statements reflect the periodic benefit costs and funded status of such plans. The Company uses September 30 as the year-end measurement date for these plans. Net periodic benefit cost for the Company’s global defined benefit pension plans for the year ended September 30, 2022 was $0.7 million. Of the plans, the defined benefit pension plan covering employees in Switzerland (the "Swiss Plan") is the only defined benefit pension plan material to the Company's Consolidated Financial Statements. Our Swiss Plan is a government-mandated retirement cash balance plan. The plan requires a minimum investment determined annually by the Swiss government and was 1.00% in 2022. Under the Swiss plan, the Company and certain employees with annual earnings in excess of government determined amounts are required to make contributions to the plan. The sum of the Company's contributions should be at least equal to the sum of employee contributions. Required minimum employee contributions are based on the respective employee’s age, salary and gender. Contributions to the Swiss Plan are invested into a diversified fund managed by an investment fiduciary. As of September 30, 2022, the Swiss plan had an unfunded net pension obligation of $0.6 million, and plan assets that totaled $8.0 million. Since Separation, we recognized net periodic benefit cost totaling $0.2 million, related to our Swiss plan, of which $0.1 million was included in Other income (expense), net . Defined Contribution Plans The Company has various defined contribution savings plans that cover substantially all employees in the United States, Ireland, and Japan. The Company matches a certain percentage of each employee’s contributions as per the provisions of the plans. Total employer contributions by the Company to the plans were $8.9 million. Between April 1, 2022 and September 30, 2022, BD remained the defined pension plan sponsor for certain Embecta employees in Ireland. The Company accounts for this plan as though it was a participant in a multi-employer plan with other businesses of BD. The amount of contributions to BD for this plan are included in the amounts noted above. At the Separation Date, Embecta effectuated an Embecta sponsored defined contribution savings plan for certain other employees in Ireland. On October 1, 2022, certain employees participation in the BD defined benefit pension plan ceased and these employees began participating in an Embecta sponsored defined contribution savings plan that was effectuated at the Separation Date. Deferred Compensation Plan On the date of the Separation, the Company established a Deferred Compensation Plan in which certain directors and employees of the Company may defer the payment and taxation of up to 75% of their base salary and up to 100% of bonus amounts and other eligible cash compensation. A participant's deferrals are “invested” at the direction of the employee in a hypothetical portfolio of investments which are tracked by an administrator. The amounts accrued under this plan were $3.7 million as of September 30, 2022.

Supplemental Financial Informat

Supplemental Financial Information	12 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Supplemental Financial Information	Supplemental Financial Information Trade Receivables, Net The amounts recognized in fiscal years 2022, 2021 and 2020 relating to allowances for doubtful accounts and cash discounts, which are netted against trade receivables, are provided in the following table: Allowance for Doubtful Accounts Allowance for Cash Discounts Total Balance at September 30, 2019 (4.2) (2.5) (6.7) Additions charged to costs and expenses (1.1) (15.2) (16.3) Deductions and other 1.4 (a) 15.5 16.9 Balance at September 30, 2020 (3.9) (2.2) (6.1) Additions charged to costs and expenses (0.3) (16.0) (16.3) Deductions and other 1.1 (a) 15.1 16.2 Balance at September 30, 2021 (3.1) (3.1) (6.2) Additions charged to costs and expenses (0.3) (18.1) (18.4) Deductions and other 2.1 (b) 21.1 23.2 Balance at September 30, 2022 (1.3) (0.1) (1.4) (a) Accounts written off (b) Amounts factored to BD Long-Lived Assets Long-lived assets, which include Property, Plant and Equipment, net , and Goodwill and Other Intangibles, net, by geographic area where located at September 30, 2022 and 2021 is as follows: 2022 2021 United States $ 109.3 $ 165.6 Europe, Middle East, and Africa 174.5 258.7 Greater Asia 42.3 50.4 Other 0.1 10.1 $ 326.2 $ 484.8

Summary of Accounting Policies

Summary of Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	On April 1, 2022, the Company became a standalone publicly traded company, and its financial statements are now presented on a consolidated basis. Prior to the Separation on April 1, 2022, the Company’s historical combined financial statements were prepared on a standalone basis and were derived from BD's consolidated financial statements and accounting records. The financial statements for all periods presented, including the historical results of the Company prior to April 1, 2022, are now referred to as "Consolidated Financial Statements", and have been prepared pursuant to the rules and regulations for reporting on Form 10-K. Periods Prior to Separation Prior to the Separation, the Company was referred to as the Diabetes Care Business. The assets, liabilities, revenue and expenses of the Diabetes Care Business were reflected in the combined financial statements on a historical cost basis, as included in the consolidated financial statements of BD, using the historical accounting policies applied by BD. The Consolidated Financial Statements did not purport to reflect what the Company’s results of operations, comprehensive income, financial position, equity or cash flows would have been had the Company operated as a standalone public company during the periods presented. The Diabetes Care Business had historically functioned together with the other businesses controlled by BD. Accordingly, the Diabetes Care Business relied on BD’s corporate and other support functions for its business. Therefore, for the period prior to the Separation, certain corporate and shared costs were allocated to the Diabetes Care Business based on a specific identification basis or, when specific identification was not practicable, a proportional cost allocation method, including: i. expenses related to BD support functions, including expenses for facilities, executive oversight, treasury, finance, legal, human resources, shared services, compliance, procurement, information technology and other corporate functions. ii. certain manufacturing and supply costs incurred by BD, including facility management, distribution, logistics, planning and global quality. iii. certain costs incurred by BD’s Medication Delivery Solutions organizational unit in relation to selling and marketing activities, and related administrative support functions. iv. certain costs incurred by BD for activities related to device research and development, as well as medical and regulatory affairs. v. stock-based compensation expenses (see Note 9). vi. certain compensation expenses maintained on a centralized basis such as certain employee benefit expenses. Management believes these cost allocations were a reasonable reflection of the utilization of services provided to, or the benefit derived by, the Diabetes Care Business during the period prior to the Separation, though the allocations may not be indicative of the actual costs that would have been incurred had the Diabetes Care Business operated as a standalone public company. Actual costs that may have been incurred if the Diabetes Care Business had been a standalone company would depend on a number of factors, including the chosen organizational structure, whether functions were outsourced or performed by Diabetes Care Business employees, and strategic decisions made in areas such as manufacturing, selling and marketing, research and development, information technology and infrastructure. BD utilized a centralized approach to cash management and the financing of its operations. Cash generated by the Diabetes Care Business was routinely transferred into accounts managed by BD’s centralized treasury function and cash disbursements related to operations prior to the Separation were funded as needed by BD. Balances held by the Diabetes Care Business with BD for cash transfers and loans were reflected as Due to related party prior to the Separation. All other cash and cash equivalents and related transfers between BD and the Diabetes Care Business were generally held centrally through accounts controlled and maintained by BD and were not specifically identifiable to the Diabetes Care Business. Accordingly, such balances were accounted for through Net Investment from Becton, Dickinson and Company . BD’s third-party debt and related interest expense were not attributed to the Diabetes Care Business because the business was not the legal obligor of the debt and the borrowings were not specifically identifiable to the business. For the Diabetes Care Business, transactions with BD affiliates were included in the Consolidated Statements of Income and related balances were reflected as Due to related party , Due from related party or Related Party Loans Payable . Other balances between the Diabetes Care Business and BD were considered to be effectively settled in the Consolidated Financial Statements at the time the transactions were recorded. As the separate legal entities that made up the Diabetes Care Business were not historically held by a single legal entity, Net Investment from Becton, Dickinson and Company was shown in lieu of stockholders’ equity in these Consolidated Financial Statements. Net Investment from Becton, Dickinson and Company represented BD’s interest in the recorded assets of the Diabetes Care Business and the cumulative investment by BD through the date of the Separation, inclusive of operating results. Income tax expense and tax balances in the Consolidated Financial Statements were calculated on a separate tax return basis. The separate tax return method applies the accounting guidance for income taxes to the standalone financial statements as if we were a separate taxpayer and a standalone enterprise. Management believes the assumptions supporting the allocation and presentation of income taxes on a separate return basis are reasonable. The provision for income taxes for the period prior to the Separation was calculated by applying an estimated effective income tax rate for the full year to ordinary income adjusted by the tax impact of discrete items. As of the Separation Date Certain assets and liabilities, including patents and unrecognized tax benefits that were included in the Consolidated Balance Sheet prior to the Separation, have been retained by BD post-Separation and therefore were transferred to BD through Net Investment from Becton, Dickinson and Company in the Company's Consolidated Financial Statements. In connection with the Separation, additional pension assets, deferred tax assets, other compensation obligations, and certain other assets and liabilities were transferred to the Company through Net Investment from Becton, Dickinson and Company , and the Company recorded these in the Consolidated Balance Sheet. As part of the Separation, Net Investment from Becton, Dickinson and Company was reclassified as Common Stock and Accumulated Deficit . Periods Post Separation Following the Separation, certain functions continue to be provided by BD under the Transition Services Agreements or are being performed using Embecta’s own resources or third-party service providers. Additionally, under manufacturing and supply agreements, the Company manufactures certain products for BD, or its applicable affiliate and BD manufactures certain products for the Company. The Company incurred certain costs in its establishment as a standalone public company and expects to incur ongoing additional costs associated with operating as an independent, publicly traded company. All intercompany transactions and accounts within Embecta have been eliminated. Certain reclassifications were made to conform the prior period Consolidated Financial Statements to the current period presentation.
Revenue Recognition and Measurement of Revenues	Revenue Recognition The Company recognizes revenue from product sales and considers performance obligations satisfied when the customer obtains control of the product, which is generally upon shipment or delivery, depending on the delivery terms specified in the sales agreement. When arrangements include multiple performance obligations, the total transaction price of the contract is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised goods or services underlying each performance obligation. The point in time upon which shipment or delivery occurs is the most faithful depiction of when control of the goods transfers to the customer. Variable consideration such as rebates, sales discounts, and sales returns are estimated and treated as a reduction of revenue in the same period the related revenue is recognized. These estimates are based on contractual terms, historical practices and current trends, and are adjusted as new information becomes available. Revenues exclude any taxes that the Company collects from customers and remits to tax authorities. Measurement of Revenues Payment terms extended to the Company’s customers are based upon commercially reasonable terms for the markets in which the Company’s products are sold. Because the Company generally expects to receive payment within one year or less from when control of a product is transferred to the customer, the Company does not generally adjust its revenues for the effects of a financing component. The Company’s allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of its trade receivables. Such estimated credit losses are determined based on historical loss experiences, customer specific credit risk, and reasonable and supportable forward-looking information, such as country or regional risks that are not captured in the historical loss information. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectible. The allowance for doubtful accounts for trade receivables is not material to the Company’s consolidated financial results.
Cash Equivalents	Cash Equivalents Cash equivalents are comprised of certain highly liquid investments with original maturities of three months or less.
Trade Receivables	Trade Receivables The Company grants credit to customers in the normal course of business and the resulting trade receivables are stated at their net realizable value. The allowance for doubtful accounts represents the Company’s estimate of probable credit losses relating to trade receivables and is determined based on historical experience, current conditions, reasonable and supportable forecasts and other specific account data. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectible.
Inventories	Inventories Inventories are stated at the lower of approximate cost or net realizable value determined on the first-in, first-out basis.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation. Depreciation is principally provided on the straight-line basis over estimated useful lives, which range from 20 to 45 years for buildings, 4 to 13 years for machinery and equipment and 1 to 20 years for leasehold improvements. Depreciation expense was $31.0 million in 2022, $37.2 million in 2021, and $36.5 million in 2020. Property, plant and equipment are periodically reviewed when impairment indicators are present to assess recoverability or a decision has been made to abandon efforts associated with construction in progress assets. Recoverability is determined by comparing the carrying values of the assets or asset groups to the undiscounted cash flows to be generated from the use and eventual disposition of such assets or asset groups. If the asset’s or asset group’s carrying value exceeds such undiscounted cash flows, the assets or asset groups are not recoverable and an impairment loss is recognized based on the amount by which the carrying value of the asset or asset group exceeds its calculated fair value.
Capitalized Interest	Capitalized InterestThe interest cost on capital projects is capitalized and included in the cost of the project. Capitalization commences with the first expenditure for the project and continues until the project is substantially complete and ready for its intended use. When no debt is incurred specifically for a project, interest is capitalized on project expenditures using the weighted average cost of the Company's outstanding borrowings.
Advertising Costs	Advertising Costs Advertising costs are expensed as incurred and included in S elling and administrative expense
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. The Company has one reporting unit. Goodwill is evaluated for impairment as of July 1 each year, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that fair value is less than carrying value. If the Company concludes it is more likely than not that fair value is less than carrying value, a quantitative fair value test is performed. If carrying value is greater than fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill). We completed the annual goodwill impairment test as of July 1, 2022 and concluded that no impairment to goodwill was necessary as the fair value of the Company's one reporting unit was significantly in excess of the carrying value. No goodwill impairments were identified during the years ended September 30, 2021, or 2020, and no accumulated impairment losses are recorded. Amortized intangible assets primarily consist of patents and customer relationships. Patents are generally amortized over 20 years using the straight-line method. Customer relationship assets are generally amortized over periods ranging from 10 to 15 years, using the straight-line method. Other intangibles with finite useful lives are amortized over periods principally ranging from 1 to 40 years, using the straight-line method. Finite-lived intangible assets are periodically reviewed when impairment indicators are present to assess recoverability from future operations using undiscounted cash flows. The carrying values of these finite-lived assets are compared to the undiscounted cash flows they are expected to generate and an impairment loss is recognized in operating results to the extent any finite-lived intangible asset’s carrying value exceeds its calculated fair value.
Foreign Currency Translation	Foreign Currency Translation Generally, foreign subsidiaries’ functional currency is the local currency of operations and the net assets of foreign operations are translated into United States dollars using current exchange rates. The United States dollar results that arise from such translation are included in Accumulated other comprehensive loss .
Shipping and Handling Costs	Shipping and Handling CostsThe Company considers its shipping and handling costs to be contract fulfillment costs and records them within selling and administrative expense.
Contingencies	ContingenciesThe Company establishes accruals for future losses which are both probable and can be reasonably estimated (and in the case of environmental matters, without considering possible third-party recoveries).
Stock-Based Compensation	Stock-Based Compensation Prior to the Separation, certain of the Company’s employees historically participated in BD’s stock-based compensation plans. Stock-based compensation expense was either allocated to the Company based on a proportionate cost allocation method or recorded based on specific identification. Effective April 1, 2022, the Company established the 2022 Employee and Director Equity Based Compensation Plan (the "Plan"). The Plan provides for the grant of various types of awards, including restricted stock unit awards, stock appreciation rights, stock options, performance-based awards and cash awards. Under the Plan, the exercise price of awards, if any, is set on the grant date and generally may not be less than the fair market value per share on that date. The Company measures stock-based compensation for equity awards at fair value on the date of grant and records stock-based compensation as a charge to earnings net of the estimated impact of forfeited awards. Accordingly, the Company recognizes stock-based compensation cost only for those stock-based awards that are estimated to ultimately vest over their requisite service period, based on the vesting provisions of the individual grants. The cumulative effect on current and prior periods of a change in the estimated forfeiture rate is recognized as compensation cost in earnings in the period of the change (see Note 9).
Benefit Plans	Benefit Plans Prior to the Separation, the defined benefit plans in which the Company participated related primarily to plans sponsored by BD and for which other businesses of BD also participate (the "Shared Plans"). The Company accounted for the Shared Plans as multiemployer plans and therefore the related assets and liabilities were not reflected in the Consolidated Balance Sheets. For such periods prior to the Separation, the Consolidated Statements of Income reflect a proportional allocation of net periodic benefit cost for the Shared Plans associated with the Company. The Company's participation in the defined pension and postretirement benefit plans sponsored by BD concluded upon the completion of the Separation on April 1, 2022. At Separation, Embecta became the plan sponsor for certain non-United States defined benefit pension plans (see Note 17).
Research and Development	Research and Development Research and development costs are expensed as incurred.
Income Taxes	Income Taxes Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement and tax basis of assets and liabilities at the applicable tax rates. We maintain valuation allowances where it is more likely than not that all or a portion of a deferred tax asset will not be realized. Changes in valuation allowances are included in the tax provision in the period of change. In determining whether a valuation allowance is warranted, we evaluate factors such as prior earnings history, expected future earnings, carryback and carryforward periods, and tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset. From time to time, the Company engages in transactions in which tax consequences may be subject to uncertainty. The Company conducts business and files tax returns in numerous jurisdictions based on its interpretation of tax laws and regulations. In evaluating the Company’s tax provision, the Company establishes a reserve for uncertain tax positions unless such positions are determined to be more likely than not of being sustained upon examination based on the technical merits. The Company’s policy is to recognize, when applicable, interest and penalties on uncertain tax positions as part of income tax expense. While the Company believes it has identified all reasonable exposures and the reserve it has established is appropriate under the circumstances, it is possible that additional exposures exist and that exposures may be settled at amounts different than the amounts reserved. It is also possible that changes in facts and circumstances could cause the Company to either materially increase or reduce the carrying amount of its tax reserve. The Tax Cuts and Jobs Act was enacted on December 22, 2017 and introduced an additional U.S. tax on certain non-US. Subsidiaries’ earnings which are referred to as Global Intangible Low Taxed Income (“GILTI”) . The Company has elected to treat GILTI as a period cost. Prior to the Separation, our operations were included in the tax returns of BD. Income taxes as presented in the Consolidated Financial Statements attribute current and deferred income tax assets and liabilities of BD to us in a manner that is systematic, rational, and consistent with the asset and liability method prescribed by the accounting guidance for income taxes. Our income tax provision prior to the Separation was prepared using the separate return method. The separate return method applies the accounting guidance for income taxes to the standalone financial statements as if we were a separate taxpayer and a standalone enterprise. We believe the assumptions supporting the allocation and presentation of income taxes on a separate return basis are reasonable. Additional disclosures regarding our accounting for income taxes are provided in Note 13.
Segment Data	Segment Data The Company operates and reports its financial information as one segment. In making this determination, the Company (i) determines its Chief Operating Decision Maker (“CODM”), (ii) identifies and analyzes potential business components, (iii) identifies its operating segments and (iv) determines whether there are multiple operating segments requiring presentation as reportable segments. The Company’s decision to report as one segment is based upon the following: (1) its internal organizational structure; (2) the manner in which its operations are managed; and (3) the criteria used by the Company’s President, its CODM, to evaluate performance of the Company’s business and allocate resources and capital.
Fair Value Measurements	Fair Value Measurements A fair value hierarchy is applied to prioritize inputs used in measuring fair value. The three levels of inputs used to measure fair value are detailed below. Additional disclosures regarding the Company’s fair value measurements are provided in Note 14. Level 1—Inputs to the valuation methodology which represent unadjusted quoted prices in active markets for identical assets and liabilities. Level 2—Inputs to the valuation methodology which include: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability. Level 3—Inputs to the valuation methodology which are unobservable and significant to the fair value measurement.
Leases	Leases We determine whether an arrangement contains a lease at inception. If a lease is identified in an arrangement, we recognize a right-of-use asset and liability in our Consolidated Balance Sheets and determine whether the lease should be classified as a finance or operating lease. We do not recognize assets or liabilities for leases with lease terms of less than 12 months. A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to Embecta by the end of the lease term, (ii) we hold an option to purchase the leased asset that we are reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases. Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the implicit rate is not readily determinable, the Company utilizes its incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease. For lease arrangements that are recognized on the Company’s Consolidated Balance Sheets, the right-of-use asset and lease liability is initially measured at the commencement date based upon the present value of the lease payments due under the lease. These payments represent the combination of the fixed lease and fixed non-lease components that are due under the arrangement. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, we reflect the option in the lease term if it is reasonably certain we will exercise the option. Finance leases are recorded in Property, Plant and Equipment, Ne t, Current finance lease liabilities , and Non Current Finance Lease Liabilities and operating leases are recorded in Deferred Income Taxes and Other Assets , Accrued expenses , and Deferred Income Taxes and Other Liabilities in our Consolidated Balance Sheets.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions. These estimates or assumptions affect reported assets, liabilities, revenues and expenses, including determining the allocation of shared costs and expenses from BD, depreciable and amortizable lives, sales returns and allowances, rebate accruals, inventory reserves and taxes on income as reflected in the Consolidated Financial Statements. Actual results could differ from these estimates. Net Investment from Becton, Dickinson and Company — Net investment from Becton, Dickinson and Company represented BD’s interest in the recorded assets of the Company and the cumulative investment by BD in the Company through the date of the Separation, inclusive of operating results and the net effect of the transactions with and allocations from BD. See Notes 2 and 4 for additional information.
Recently Adopted Accounting Standards and Recently Issued Accounting Standards Not Yet Adopted	Recently Adopted Accounting Standards In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12, Income Taxes - Simplifying the Accounting for Income Taxes (Topic 740). The updated guidance simplifies the accounting for income taxes by removing certain exceptions in Topic 740 and clarifying and amending existing guidance. The amendments are effective for fiscal years beginning after December 15, 2020, with early adoption permitted. The Company adopted the provisions of this new accounting standard at the beginning of fiscal 2022 and adoption did not have a material impact on its consolidated financial statements. Recently Issued Accounting Standards Not Yet Adopted In October 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2021-08, "Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts

Third Party Arrangements and _2

Third Party Arrangements and Related Party Disclosures (Tables)	12 Months Ended
	Sep. 30, 2022
Third Party and Related Party Transactions [Abstract]
Schedule of Related Party Transactions	The allocations of General Corporate Expenses are reflected in the Consolidated Statements of Income as follows: Year ended September 30, 2022 2021 2020 Cost of products sold $ 2.3 $ 13.0 $ 9.2 Selling and administrative expense 47.9 98.3 80.2 Research and development expense 3.5 5.2 5.4 Other (income) expense, net (0.6) (1.3) 0.5 Total General Corporate Expenses $ 53.1 $ 115.2 $ 95.3 Year ended September 30, 2022 2021 2020 Purchases from BD $ 28.0 $ 40.6 $ 43.4 The following table summarizes the components of the net transfers to BD as follows: Year ended September 30, 2022 2021 2020 Cash pooling and general financing activities (1) $ 255.9 $ 599.5 $ 591.8 Corporate and segment allocations, excluding non-cash stock-based compensation (50.4) (109.9) (90.4) Taxes deemed settled with BD (16.2) (72.5) (44.8) Other Separation related adjustments, net (11.4) — — Net transfers to BD as reflected in the Consolidated Statements of Cash Flows 177.9 417.1 456.6 Share-based compensation expense (8.5) (12.5) (12.7) Pension expense (3.6) (9.4) (9.4) Net Consideration paid to BD in connection with the Separation 1,266.0 — — Related party senior secured notes 197.0 — — Other transfers to (from) BD, net 84.1 (11.4) 14.4 Net transfers to BD $ 1,712.9 $ 383.8 $ 448.9

Segment and Geographical Data (

Segment and Geographical Data (Tables)	12 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Schedule of Revenues by Geographical Region	Revenues by geographic region are as follows: Year ended September 30, 2022 2021 2020 United States $ 600.3 $ 609.4 $ 563.0 International (1) 529.2 555.9 522.5 Total $ 1,129.5 $ 1,165.3 $ 1,085.5

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-Based Compensation Expense	Total direct and allocated stock-based compensation expense for the years ended September 30, 2022, 2021, and 2020 and the respective income tax benefits recognized by the Company in the Consolidated Statements of Income are as follows: 2022 2021 2020 Cost of products sold $ 2.3 $ 2.7 $ 2.4 Selling and administrative expense 14.6 7.8 7.8 Research and development expense 1.8 2.3 2.2 Total Stock-Based Compensation Expense $ 18.7 $ 12.8 $ 12.4 Tax benefit associated with stock-based compensation costs recognized $ 2.9 $ 2.8 $ 3.0
Schedule of SARs Valuation Assumptions	The weighted average fair value of SARs was determined using the following assumptions: 2022 Risk-free interest rate 2.5 % Expected volatility 37.8 % Expected dividend yield 2.9 % Expected life 6.5 Fair value per SAR $ 9.38
Schedule of SAR's Outstanding and Changes	A summary of SARs outstanding as of September 30, 2022 and changes since the Separation Date are as follows: SARs (in thousands) Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Balance at April 1 1,379.8 $ 27.70 Granted 660.2 31.40 Exercised* (9.0) 13.66 Forfeited, canceled or expired (114.3) $ 28.64 Balance at September 30 1,916.7 $ 28.98 8.7 $ 1.4 Vested and expected to vest at September 30 1,824.0 $ 28.96 8.7 $ 1.4 Exercisable at September 30 230.6 $ 25.71 6.2 $ 0.8 *The amounts exercised include shares withheld for taxes that are not formally issued to the market.
Schedule of Restricted Stock Units Outstanding and Changes	A summary of time-vested restricted stock units outstanding as of September 30, 2022 and changes since the Separation Date are as follows: Stock Units (in thousands) Weighted Average Grant Date Fair Value Nonvested at April 1 847.0 $ 27.41 Granted 248.6 31.23 Distributed* (58.5) 27.41 Forfeited, canceled or expired (59.6) 28.03 Nonvested at September 30 977.5 $ 28.34 Expected to vest at September 30 930.8 $ 28.34 *The amounts distributed include shares withheld for taxes that are not formally issued to the market.

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets consisted of: Weighted Average Amortization Period (Years) September 30, 2022 September 30, 2021 Amortized intangible assets Patents – gross 13.0 $ 9.4 $ 20.8 Less: accumulated amortization (3.9) (6.5) Patents – net $ 5.5 $ 14.3 Customer Relationships and Other – gross 6.9 $ 5.2 $ 5.4 Less: accumulated amortization (1.8) (1.4) Customer Relationships and Other – net $ 3.4 $ 4.0 Total amortized intangible assets $ 8.9 $ 18.3 Goodwill 15.7 15.6 Total Goodwill and Other Intangible Assets $ 24.6 $ 33.9

Long-Term Debt (Tables)

Long-Term Debt (Tables)	12 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Schedule of Debt Outstanding	The following is a summary of Embecta's total debt outstanding as of September 30, 2022: Term Loan $ 945.3 5.00% Notes 500.0 6.75% Notes 200.0 Total principal debt issued $ 1,645.3 Less: current debt obligations (9.5) Less: debt issuance costs and discounts (37.7) Long-term debt $ 1,598.1
Schedule of Principal Payments Required on Long-Term Debt	The schedule of principal payments required on long-term debt for the next five fiscal years and thereafter is as follows: 2023 $ 9.5 2024 $ 9.5 2025 $ 9.5 2026 $ 9.5 2027 $ 9.5 Thereafter $ 1,597.8

Earnings per Share (Tables)

Earnings per Share (Tables)	12 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Earnings per Share	The calculation of basic and diluted earnings per common share for the years ended September 30, 2022, 2021 and 2020 were as follows: ($ in millions and shares in thousands, except per share amounts) 2022 2021 2020 Net Income attributable to Embecta $ 223.6 $ 414.8 $ 427.6 Basic weighted average number of shares outstanding 57,024 57,013 57,013 Stock awards and equity units (share equivalent) 437 — — Diluted weighted average shares outstanding 57,461 57,013 57,013 Earnings per common share - Basic $ 3.92 $ 7.28 $ 7.50 Earnings per common share - Diluted $ 3.89 $ 7.28 $ 7.50

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Schedule of Income before Income Taxes	The components of Income Before Income Taxes for the years ended September 30 consisted of: 2022 2021 2020 Domestic $ (29.1) $ 87.5 $ 73.8 Foreign 285.7 407.4 412.0 Income before income taxes $ 256.6 $ 494.9 $ 485.8
Schedule of Components of Provision (Benefit) for Income Taxes	The provision (benefit) for income taxes for the years ended September 30 consisted of: 2022 2021 2020 Current: Federal $ 20.4 $ 19.2 $ 1.0 State 3.4 4.3 3.7 Foreign 35.7 59.4 55.7 $ 59.5 $ 82.9 $ 60.4 Deferred: Federal $ (31.1) $ (1.3) $ (2.7) State (4.6) (0.3) — Foreign 9.2 (1.2) 0.5 $ (26.5) $ (2.8) $ (2.2) Income tax provision $ 33.0 $ 80.1 $ 58.2 The following were included for the years ended September 30 as a component of Income tax provision in the Consolidated Statements of Income. 2022 2021 2020 Interest and penalties associated with unrecognized tax benefits $ 1.5 $ 4.0 $ 2.9
Schedule of Tax Rate Reconciliation	A reconciliation of federal statutory tax rate to the Company's effective income tax rate was as follows: 2022 2021 2020 Federal statutory tax rate 21.0 % 21.0 % 21.0 % State and local income taxes, net of federal tax benefit (0.8) 0.7 0.6 Foreign income tax at rates other than 21% (7.0) (6.1) (6.7) US tax on foreign earnings 0.2 0.5 0.5 Taxes on unremitted foreign earnings 3.2 — — Tax reserves (1.8) 0.5 (3.0) Tax credits (0.7) (0.4) (0.4) Nontaxable items (1.1) — — Other, net (0.1) — — Effective income tax rate 12.9 % 16.2 % 12.0 %
Schedule of Deferred Income Taxes	Deferred income taxes at September 30 consisted of: 2022 2021 Deferred tax assets: Compensation and benefits $ 8.6 $ 2.1 Accruals and reserves 10.3 5.3 Intangibles 26.2 — Property, plant and equipment 19.0 — Capitalized research and development expenses 7.0 — Leases 9.7 — Tax loss and credit carryforwards 0.5 0.3 Other 5.4 1.6 Gross deferred tax assets before valuation allowance $ 86.7 $ 9.3 Valuation allowance $ (10.4) $ (0.3) Total deferred tax assets $ 76.3 $ 9.0 Deferred tax liabilities: Property, plant and equipment $ — $ (8.3) Taxes on unremitted foreign earnings (8.2) — Right of use asset (9.5) — Other — (2.0) Total deferred tax liabilities $ (17.7) $ (10.3) Net deferred tax assets (liabilities) (i) $ 58.6 $ (1.3) i. Net deferred tax assets are included in Deferred Income Taxes and Other Assets and net deferred tax liabilities are included in Deferred Income Taxes and Other Liabilities in the Consolidated Balance Sheets.
Schedule of Unrecognized Tax Benefits	The table below summarizes the gross amounts of unrecognized tax benefits without regard to reduction in tax liabilities or additions to deferred tax assets and liabilities if such unrecognized tax benefits were settled. The Company believes it is reasonably possible that the amount of unrecognized tax benefits will change due to one or more of the following events in the next twelve months: expiring statutes, audit activity, and tax payments in matters that are the subject of controversy in various taxing jurisdictions in which the Company operates. 2022 2021 2020 Balance at October 1 $ 16.0 $ 14.5 $ 28.4 Increase due to current year tax positions 1.0 1.3 0.8 Increase due to prior year tax positions — 0.3 0.1 Decrease due to prior year tax positions (6.7) — (14.8) Decrease due to settlements with tax authorities — (0.1) — Decrease due to lapse of statute of limitations (4.6) — — Balance at September 30 $ 5.7 $ 16.0 $ 14.5 Unrecognized tax benefits including interest and penalties that would affect the effective tax rate if recognized $ 7.2 $ 20.0 $ 17.4

Financial Instruments and Fai_2

Financial Instruments and Fair Value Measurements (Tables)	12 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Cash and Cash Equivalents	The following reconciles Cash and cash equivalents reported within the Consolidated Balance Sheets as of September 30, 2022 and September 30, 2021, to the total amounts shown in the Consolidated Statements of Cash Flows: September 30, 2022 September 30, 2021 Cash and cash equivalents $ 330.9 $ —
Schedule of Notional Amounts of Derivative Instruments	The notional amounts of the Company’s foreign currency-related derivative instruments were as follows: Hedge Designation September 30, 2022 September 30, 2021 Foreign exchange contracts (a) Undesignated $ 5.1 $ — a. Represent hedges of transactional foreign exchange exposures resulting primarily from intercompany payables and receivables. Gains and losses on these instruments are recognized immediately in Other income (expense), net . These gains and losses are largely offset by gains and losses on the underlying hedged items, as well as the hedging costs associated with the derivative instruments. Gains and losses recognized to date on these instruments were not material to the Company's Consolidated Financial Statements.

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property, Plant and Equipment, Net consisted of: As of September 30, 2022 As of September 30, 2021 Land $ 1.4 $ 3.5 Buildings 123.7 120.4 Machinery, equipment and fixtures 505.1 570.8 Leasehold improvements 6.5 6.1 Construction in progress 64.9 190.8 $ 701.6 $ 891.6 Less: accumulated depreciation (400.0) (440.7) Total Property, Plant and Equipment, Net $ 301.6 $ 450.9

Leases (Tables)

Leases (Tables)	12 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Schedule of Balance Sheet Information	Our leases are included in our Consolidated Balance Sheets as follows: As of September 30, 2022 As of September 30, 2021 Finance Lease Property, Plant, and Equipment, Net $ 35.5 $ — Total Finance Lease Assets $ 35.5 $ — Current finance lease liabilities $ 3.6 $ — Non Current Finance Lease Liabilities 32.6 — Total Finance Lease Liabilities $ 36.2 $ — Weighted-average remaining lease term (years) 14.5 — Weighted-average discount rate 6.8 % — Operating Leases Deferred Income Taxes and Other Assets $ 6.3 $ 3.9 Total Operating Lease Assets $ 6.3 $ 3.9 Accrued expenses $ 2.0 $ 1.1 Deferred Income Taxes and Other Liabilities 4.3 3.0 Total Operating Lease Liabilities $ 6.3 $ 4.1 Weighted-average remaining lease term (years) 3.2 4.3 Weighted-average discount rate 5.9 % 2.2 %
Schedule of Supplemental Cash Flow Information	Supplemental cash flow information related to leases for the year ended September 30, 2022 was as follows: September 30, 2022 Right of use assets obtained in exchange for lease liabilities Financing Lease $ 36.7 Operating Leases 2.8
Schedule of Maturities of Finance Lease Liabilities	Maturities of our finance and operating lease liabilities as of September 30, 2022 by fiscal year are as follows: Finance Leases Operating Leases Total 2023 3.6 2.3 5.9 2024 3.6 2.1 5.7 2025 3.7 1.2 4.9 2026 3.7 1.0 4.7 2027 3.8 — 3.8 Thereafter 40.1 — 40.1 Total lease payments $ 58.5 $ 6.6 $ 65.1 Less: amount representing interest 22.3 0.3 22.6 Present value of lease liabilities $ 36.2 $ 6.3 $ 42.5
Schedule of Maturities of Operating Lease Liabilities	Maturities of our finance and operating lease liabilities as of September 30, 2022 by fiscal year are as follows: Finance Leases Operating Leases Total 2023 3.6 2.3 5.9 2024 3.6 2.1 5.7 2025 3.7 1.2 4.9 2026 3.7 1.0 4.7 2027 3.8 — 3.8 Thereafter 40.1 — 40.1 Total lease payments $ 58.5 $ 6.6 $ 65.1 Less: amount representing interest 22.3 0.3 22.6 Present value of lease liabilities $ 36.2 $ 6.3 $ 42.5

Supplemental Financial Inform_2

Supplemental Financial Information (Tables)	12 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Allowance for Doubtful Accounts and Cash Discounts	The amounts recognized in fiscal years 2022, 2021 and 2020 relating to allowances for doubtful accounts and cash discounts, which are netted against trade receivables, are provided in the following table: Allowance for Doubtful Accounts Allowance for Cash Discounts Total Balance at September 30, 2019 (4.2) (2.5) (6.7) Additions charged to costs and expenses (1.1) (15.2) (16.3) Deductions and other 1.4 (a) 15.5 16.9 Balance at September 30, 2020 (3.9) (2.2) (6.1) Additions charged to costs and expenses (0.3) (16.0) (16.3) Deductions and other 1.1 (a) 15.1 16.2 Balance at September 30, 2021 (3.1) (3.1) (6.2) Additions charged to costs and expenses (0.3) (18.1) (18.4) Deductions and other 2.1 (b) 21.1 23.2 Balance at September 30, 2022 (1.3) (0.1) (1.4) (a) Accounts written off (b) Amounts factored to BD
Schedule of Long-Lived Assets by Geographic Area	Long-lived assets, which include Property, Plant and Equipment, net , and Goodwill and Other Intangibles, net, by geographic area where located at September 30, 2022 and 2021 is as follows: 2022 2021 United States $ 109.3 $ 165.6 Europe, Middle East, and Africa 174.5 258.7 Greater Asia 42.3 50.4 Other 0.1 10.1 $ 326.2 $ 484.8

Background (Details)

Background (Details)	Apr. 01, 2022 $ / shares	Sep. 30, 2022 $ / shares
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Common stock, distribution ratio	0.2
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Becton, Dickinson and Company
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Common stock, par value (in dollars per share)	$ 1

Summary of Accounting Policie_2

Summary of Accounting Policies (Details)	12 Months Ended
	Sep. 30, 2022 USD ($) segment reporting_unit	Sep. 30, 2021 USD ($)	Sep. 30, 2020 USD ($)
Summary Of Accounting Policies [Line Items]
Depreciation	$ 31,000,000	$ 37,200,000	$ 36,500,000
Interest expense capitalized	5,200,000
Advertising costs	$ 11,600,000	9,300,000	8,200,000
Number of reporting units | reporting_unit	1
Goodwill impairments		0	0
Accumulated impairment loss		0	0
Selling and administrative expense	$ 294,800,000	240,300,000	214,700,000
Number of operating segments | segment	1
Number of reportable segments | segment	1
Cash paid for interest, net of interest capitalized	$ 38,900,000
Debt outstanding		0	0
Cash paid for income taxes, net of refunds	15,600,000
Shipping and Handling
Summary Of Accounting Policies [Line Items]
Selling and administrative expense	$ 27,400,000	$ 13,600,000	$ 12,400,000
Patents
Summary Of Accounting Policies [Line Items]
Intangible assets useful life	20 years
Minimum | Customer Relationships
Summary Of Accounting Policies [Line Items]
Intangible assets useful life	10 years
Minimum | Other Intangible Assets
Summary Of Accounting Policies [Line Items]
Intangible assets useful life	1 year
Maximum | Customer Relationships
Summary Of Accounting Policies [Line Items]
Intangible assets useful life	15 years
Maximum | Other Intangible Assets
Summary Of Accounting Policies [Line Items]
Intangible assets useful life	40 years
Buildings | Minimum
Summary Of Accounting Policies [Line Items]
Property, plant and equipment useful life	20 years
Buildings | Maximum
Summary Of Accounting Policies [Line Items]
Property, plant and equipment useful life	45 years
Machinery and equipment | Minimum
Summary Of Accounting Policies [Line Items]
Property, plant and equipment useful life	4 years
Machinery and equipment | Maximum
Summary Of Accounting Policies [Line Items]
Property, plant and equipment useful life	13 years
Leasehold improvements | Minimum
Summary Of Accounting Policies [Line Items]
Property, plant and equipment useful life	1 year
Leasehold improvements | Maximum
Summary Of Accounting Policies [Line Items]
Property, plant and equipment useful life	20 years

Third Party Arrangements and _3

Third Party Arrangements and Related Party Disclosures - Additional Information (Details) - USD ($)		12 Months Ended
	Apr. 01, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020	Mar. 31, 2022
Related Party Transaction [Line Items]
Amounts due from Becton, Dickinson and Company		$ 110,900,000	$ 0
Amounts due to Becton, Dickinson and Company		66,500,000	0
Cost of products sold from related party inventory purchases		28,000,000	$ 40,600,000	$ 43,400,000
6.75% Senior Secured Notes due 2030 | Senior Notes
Related Party Transaction [Line Items]
Face amount	$ 200,000,000
6.75% Senior Secured Notes due 2030 | Senior Notes | Parent
Related Party Transaction [Line Items]
Face amount					$ 200,000,000
Becton, Dickinson and Company
Related Party Transaction [Line Items]
Cannula Supply Agreement, minimum notice period to terminate agreement	36 months
Cannula Supply Agreement, minimum period from distribution date to terminate agreement	10 years
Becton, Dickinson and Company
Related Party Transaction [Line Items]
Transaction Services Agreement, maximum period	24 months
Trade Receivables Factoring Agreement Service fee as a percentage of annual revenue	0.10%
Distribution Agreement, maximum term for distributor appointed	2 years
Cannula Supply Agreement, minimum notice period to terminate agreement	36 months
Cannula Supply Agreement, minimum period from distribution date to terminate agreement	5 years
Cannula Supply Agreement, termination related to yearly forecasted purchase minimum, wind-down period	36 months
Tax Matters Agreement, covenant restrictions period	2 years
Tax Matters Agreement, covenant restrictions, change in stock ownership threshold	50%
Logistics Services Agreement, maximum term	2 years
Logistics Services Agreement, administrative fee as a percentage of net revenue	1%
Amounts due from Becton, Dickinson and Company		110,900,000
Amounts due to Becton, Dickinson and Company		$ 66,500,000
Becton, Dickinson and Company | Minimum
Related Party Transaction [Line Items]
Distribution Agreement, fee paid as a percentage of net revenue for each territory	1.50%
Becton, Dickinson and Company | Maximum
Related Party Transaction [Line Items]
Distribution Agreement, fee paid as a percentage of net revenue for each territory	2%

Third Party Arrangements and _4

Third Party Arrangements and Related Party Disclosures - Allocation of General Corporate Expenses (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Related Party Transaction [Line Items]
General Corporate Expenses	$ 53.1	$ 115.2	$ 95.3
Cost of products sold
Related Party Transaction [Line Items]
General Corporate Expenses	2.3	13	9.2
Selling and administrative expense
Related Party Transaction [Line Items]
General Corporate Expenses	47.9	98.3	80.2
Research and development expense
Related Party Transaction [Line Items]
General Corporate Expenses	3.5	5.2	5.4
Other (income) expense, net
Related Party Transaction [Line Items]
General Corporate Expenses	$ (0.6)	$ (1.3)	$ 0.5

Third Party Arrangements and _5

Third Party Arrangements and Related Party Disclosures - Purchases from Parent (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Parent
Related Party Transaction [Line Items]
Purchases from BD	$ 28	$ 40.6	$ 43.4

Third Party Arrangements and _6

Third Party Arrangements and Related Party Disclosures - Net Transfers to Parent (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Third Party and Related Party Transactions [Abstract]
Cash pooling and general financing activities	$ 255.9	$ 599.5	$ 591.8
Corporate and segment allocations, excluding non-cash stock-based compensation	(50.4)	(109.9)	(90.4)
Taxes deemed settled with BD	(16.2)	(72.5)	(44.8)
Other Separation related adjustments, net	(11.4)	0	0
Net transfers to BD as reflected in the Consolidated Statements of Cash Flows	177.9	417.1	456.6
Share-based compensation expense	(8.5)	(12.5)	(12.7)
Pension expense	(3.6)	(9.4)	(9.4)
Net Consideration paid to BD in connection with the Separation	1,266	0	0
Related party senior secured notes	197	0	0
Other transfers to (from) BD, net	84.1	(11.4)	14.4
Net transfers to BD	$ 1,712.9	$ 383.8	$ 448.9

Other Operating Expenses (Detai

Other Operating Expenses (Details) - USD ($)	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Other Income and Expenses [Abstract]
Separation and stand-up costs	$ 44,700,000	$ 4,800,000	$ 0

Revenues (Details)

Revenues (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Revenue from Contract with Customer [Abstract]
Customer rebate liability	$ 43.8	$ 71.7
Rebates recorded	336.4	298.7	$ 300.7
Contract asset	$ 1.2	$ 1.4

Segment and Geographical Data_2

Segment and Geographical Data (Details) $ in Millions	12 Months Ended
	Sep. 30, 2022 USD ($) segment	Sep. 30, 2021 USD ($)	Sep. 30, 2020 USD ($)
Segment Reporting [Abstract]
Number of operating segments | segment	1
Segment Reporting Information [Line Items]
Revenues	$ 1,129.5	$ 1,165.3	$ 1,085.5
United States
Segment Reporting Information [Line Items]
Revenues	600.3	609.4	563
International
Segment Reporting Information [Line Items]
Revenues	$ 529.2	$ 555.9	$ 522.5

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions			6 Months Ended		12 Months Ended
	Apr. 04, 2022	Apr. 01, 2022	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Unrecognized compensation expense			$ 27.8	$ 27.8	$ 27.8
Grant date fair value of awards exercised			$ 6.1
Weighted average remaining term of awards			8 years 8 months 12 days
Period for recognition for unrecognized compensation expense					2 years 2 months 12 days
Employee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Awards granted (in shares)	860,611
SARs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Intrinsic value of awards exercised			$ 0.1
SARs | Employee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Vesting period	3 years
Awards granted (in shares)	528,167
SARs | Employee | CEO
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Vesting period	4 years
Awards granted (in shares)	132,004
RSUs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Vesting period	3 years
Awards granted (in shares)			248,600
Weighted average grant date fair value of awards granted (in dollars per share)			$ 31.23
Fair value of awards vested			$ 1.6
Weighted average remaining term of awards			1 year 8 months 12 days
RSUs | Nonemployee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Awards granted (in shares)		48,192
RSUs | Employee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Vesting period	3 years
Awards granted (in shares)	172,787
RSUs | Employee | CEO
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Vesting period	3 years
Awards granted (in shares)	27,653
Maximum | RSUs | Nonemployee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Vesting period		1 year
2022 Employee and Director Equity Based Compensation Plan
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total incremental cost to be recognized		$ 6.1
Incremental cost recognized				2.3
Unrecognized compensation expense			$ 3.8	$ 3.8	$ 3.8
Number of shares authorized (in shares)		7,000,000
Number of shares authorized for future grant			4,100,000	4,100,000	4,100,000
2022 Employee and Director Equity Based Compensation Plan | SARs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award term		10 years
2022 Employee and Director Equity Based Compensation Plan | Minimum | SARs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Vesting period		3 years
2022 Employee and Director Equity Based Compensation Plan | Maximum | SARs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Vesting period		4 years

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total Stock-Based Compensation Expense	$ 18.7	$ 12.8	$ 12.4
Tax benefit associated with stock-based compensation costs recognized	2.9	2.8	3
Cost of products sold
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total Stock-Based Compensation Expense	2.3	2.7	2.4
Selling and administrative expense
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total Stock-Based Compensation Expense	14.6	7.8	7.8
Research and development expense
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total Stock-Based Compensation Expense	$ 1.8	$ 2.3	$ 2.2

Stock-Based Compensation - SARs

Stock-Based Compensation - SARs Valuation Assumptions (Details) - SARs	12 Months Ended
	Sep. 30, 2022 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	2.50%
Expected volatility	37.80%
Expected dividend yield	2.90%
Expected life	6 years 6 months
Fair value per SAR (in dollars per share)	$ 9.38

Stock-Based Compensation - SA_2

Stock-Based Compensation - SARs Outstanding and the Changes (Details) $ / shares in Units, $ in Millions	6 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares
Additional Disclosures
Outstanding, Weighted Average Remaining Contractual Term (Years)	8 years 8 months 12 days
Outstanding, Aggregate Intrinsic Value | $	$ 1.4
Vested and expected to vest, Weighted Average Remaining Contractual Term (Years)	8 years 8 months 12 days
Vested and expected to vest, Aggregate Intrinsic Value | $	$ 1.4
Exercisable, Weighted Average Remaining Contractual Term (Years)	6 years 2 months 12 days
Exercisable, Aggregate Intrinsic Value | $	$ 0.8
SARs
SARs (in thousands)
Outstanding, Beginning Balance (in shares) | shares	1,379,800
Granted (in shares) | shares	660,200
Exercised (in shares) | shares	(9,000)
Forfeited, canceled or and expired (in shares) | shares	(114,300)
Outstanding, Ending Balance (in shares) | shares	1,916,700
Weighted Average Exercise Price
Outstanding, Beginning Balance (in dollars per share) | $ / shares	$ 27.70
Granted (in dollars per share) | $ / shares	31.40
Exercised (in dollars per share) | $ / shares	13.66
Forfeited, canceled or expired (in dollars per share) | $ / shares	28.64
Outstanding, Ending Balance (in dollars per share) | $ / shares	$ 28.98
Additional Disclosures
Vested and expected to vest (in shares) | shares	1,824,000
Vested and expected to vest, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 28.96
Exercisable (in shares) | shares	230,600
Exercisable, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 25.71

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Units Outstanding and Activity (Details) - RSUs	6 Months Ended
	Sep. 30, 2022 $ / shares shares
Stock Units (in thousands)
Nonvested, Beginning Balance (in shares) | shares	847,000
Granted (in shares) | shares	248,600
Distributed (in shares) | shares	(58,500)
Forfeited, canceled or expired (in shares) | shares	(59,600)
Nonvested, Ending Balance (in shares) | shares	977,500
Expected to vest (in shares) | shares	930,800
Weighted Average Grant Date Fair Value
Nonvested, Beginning Balance (in dollars per share) | $ / shares	$ 27.41
Granted (in dollars per share) | $ / shares	31.23
Distributed (in dollars per share) | $ / shares	27.41
Forfeited, canceled or expired (in dollars per share) | $ / shares	28.03
Nonvested, Ending Balance (in dollars per share) | $ / shares	28.34
Expected to vest (in dollars per share) | $ / shares	$ 28.34

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets - Summary (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Finite-Lived Intangible Assets [Line Items]
Amortized intangible assets - net	$ 8.9	$ 18.3
Goodwill	15.7	15.6
Total Goodwill and Other Intangible Assets	$ 24.6	33.9
Patents
Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Period (Years)	13 years
Amortized intangible assets - gross	$ 9.4	20.8
Amortized intangible assets - accumulated amortization	(3.9)	(6.5)
Amortized intangible assets - net	$ 5.5	14.3
Customer Relationship and Other
Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Period (Years)	6 years 10 months 24 days
Amortized intangible assets - gross	$ 5.2	5.4
Amortized intangible assets - accumulated amortization	(1.8)	(1.4)
Amortized intangible assets - net	$ 3.4	$ 4

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible asset amortization expense	$ 0.7	$ 0.3	$ 0.3
Estimated intangible asset amortization expense for 2023	1.1
Estimated intangible asset amortization expense for 2024	1.1
Estimated intangible asset amortization expense for 2025	1.1
Estimated intangible asset amortization expense for 2026	1.1
Estimated intangible asset amortization expense for 2027	1.1
Estimated intangible asset amortization expense for subsequent years thereafter	$ 3.4

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Details) - USD ($)	Mar. 31, 2022	Sep. 30, 2022	Apr. 01, 2022	Feb. 10, 2022
Level 2 | Fair Value
Debt Instrument [Line Items]
Long-term debt		$ 1,531,300,000
Level 2 | Reported Value Measurement
Debt Instrument [Line Items]
Long-term debt		$ 1,607,600,000
5.00% Senior Secured Notes due 2030 | Senior Notes
Debt Instrument [Line Items]
Stated interest rate		5%		5%
Face amount				$ 500,000,000
6.75% Senior Secured Notes due 2030 | Senior Notes
Debt Instrument [Line Items]
Stated interest rate		6.75%	6.75%
Face amount			$ 200,000,000
6.75% Senior Secured Notes due 2030 | Senior Notes | Parent
Debt Instrument [Line Items]
Face amount	$ 200,000,000
Related party interest rate	6.75%
Discount	$ 3,000,000
Term Loan | Secured Debt
Debt Instrument [Line Items]
Face amount	$ 950,000,000
Term	7 years
Discount percentage	0.50%
Quarterly payment as a percentage of principal	0.25%
Term Loan | Secured Debt | SOFR
Debt Instrument [Line Items]
Basis spread on variable rate	3%
Variable rate floor	0.50%
Revolving Credit Facility | Secured Debt | Revolving Credit Facility
Debt Instrument [Line Items]
Term	5 years
Maximum borrowing capacity	$ 500,000,000
Commitment fee percentage	0.25%
Amount drawn		$ 0

Long-Term Debt - Debt Outstandi

Long-Term Debt - Debt Outstanding (Details) - USD ($) $ in Millions	Sep. 30, 2022	Apr. 01, 2022	Feb. 10, 2022	Sep. 30, 2021
Debt Instrument [Line Items]
Total principal debt issued	$ 1,645.3
Less: current debt obligations	(9.5)			$ 0
Less: debt issuance costs and discounts	(37.7)
Long-term debt	1,598.1			$ 0
Secured Debt | Term Loan
Debt Instrument [Line Items]
Total principal debt issued	$ 945.3
Senior Notes | 5.00% Notes
Debt Instrument [Line Items]
Stated interest rate	5%		5%
Total principal debt issued	$ 500
Senior Notes | 6.75% Notes
Debt Instrument [Line Items]
Stated interest rate	6.75%	6.75%
Total principal debt issued	$ 200

Long-Term Debt - Principal Paym

Long-Term Debt - Principal Payments Required on Long-Term Debt (Details) $ in Millions	Sep. 30, 2022 USD ($)
Debt Disclosure [Abstract]
2023	$ 9.5
2024	9.5
2025	9.5
2026	9.5
2027	9.5
Thereafter	$ 1,597.8

Earnings per Share - Additional

Earnings per Share - Additional Information (Details) - $ / shares		12 Months Ended
	Apr. 01, 2022	Sep. 30, 2022
Earnings Per Share [Abstract]
Shares distributed (in shares)	57,012,925
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Antidilutive securities excluded from computation of earnings per share (in shares)		1,800,000

Earnings per Share - Computatio

Earnings per Share - Computation of Earnings per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Earnings Per Share [Abstract]
Net Income attributable to Embecta	$ 223.6	$ 414.8	$ 427.6
Basic weighted average number of shares outstanding (in shares)	57,024	57,013	57,013
Stock awards and equity units (share equivalent) (in shares)	437	0	0
Diluted weighted average shares outstanding (in shares)	57,461	57,013	57,013
Earnings per common share - Basic (in dollars per share)	$ 3.92	$ 7.28	$ 7.50
Earnings per common share - Diluted (in dollars per share)	$ 3.89	$ 7.28	$ 7.50

Income Taxes - Income Before In

Income Taxes - Income Before Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Domestic	$ (29.1)	$ 87.5	$ 73.8
Foreign	285.7	407.4	412
Income Before Income Taxes	$ 256.6	$ 494.9	$ 485.8

Income Taxes - Provision (Benef

Income Taxes - Provision (Benefit) for Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Current:
Federal	$ 20.4	$ 19.2	$ 1
State	3.4	4.3	3.7
Foreign	35.7	59.4	55.7
Current total	59.5	82.9	60.4
Deferred:
Federal	(31.1)	(1.3)	(2.7)
State	(4.6)	(0.3)	0
Foreign	9.2	(1.2)	0.5
Deferred total	(26.5)	(2.8)	(2.2)
Income tax provision	$ 33	$ 80.1	$ 58.2

Income Taxes - Tax Rate Reconci

Income Taxes - Tax Rate Reconciliation (Details)	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Federal statutory tax rate	21%	21%	21%
State and local income taxes, net of federal tax benefit	(0.80%)	0.70%	0.60%
Foreign income tax at rates other than 21%	(7.00%)	(6.10%)	(6.70%)
US tax on foreign earnings	0.20%	0.50%	0.50%
Taxes on unremitted foreign earnings	3.20%	0%	0%
Tax reserves	(1.80%)	0.50%	(3.00%)
Tax credits	(0.70%)	(0.40%)	(0.40%)
Nontaxable items	(1.10%)	0%	0%
Other, net	(0.10%)	0%	0%
Effective income tax rate	12.90%	16.20%	12%

Income Taxes - Deferred Income

Income Taxes - Deferred Income Taxes (Details) - USD ($) $ in Millions	Sep. 30, 2022	Sep. 30, 2021
Deferred tax assets:
Compensation and benefits	$ 8.6	$ 2.1
Accruals and reserves	10.3	5.3
Intangibles	26.2	0
Property, plant and equipment	19	0
Capitalized research and development expenses	7	0
Leases	9.7	0
Tax loss and credit carryforwards	0.5	0.3
Other	5.4	1.6
Gross deferred tax assets before valuation allowance	86.7	9.3
Valuation allowance	(10.4)	(0.3)
Total deferred tax assets	76.3	9
Deferred tax liabilities:
Property, plant and equipment	0	(8.3)
Taxes on unremitted foreign earnings	(8.2)	0
Right of use asset	(9.5)	0
Other	0	(2)
Total deferred tax liabilities	(17.7)	(10.3)
Net deferred tax assets	$ 58.6
Net deferred tax liabilities		$ (1.3)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Millions	Sep. 30, 2022	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Valuation allowances	$ 10.4	$ 0.3

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning balance	$ 16	$ 14.5	$ 28.4
Increase due to current year tax positions	1	1.3	0.8
Increase due to prior year tax positions	0	0.3	0.1
Decrease due to prior year tax positions	(6.7)	0	(14.8)
Decrease due to settlements with tax authorities	0	(0.1)	0
Decrease due to lapse of statute of limitations	(4.6)	0	0
Ending balance	5.7	16	14.5
Unrecognized tax benefits including interest and penalties that would affect the effective tax rate if recognized	$ 7.2	$ 20	$ 17.4

Income Taxes - Interest and Pen

Income Taxes - Interest and Penalties (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Interest and penalties associated with unrecognized tax benefits	$ 1.5	$ 4	$ 2.9

Financial Instruments and Fai_3

Financial Instruments and Fair Value Measurements - Cash and Cash Equivalents (Details) - USD ($) $ in Millions	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Cash and cash equivalents - condensed combined balance sheets	$ 330.9	$ 0
Cash and cash equivalents - condensed combined statements of cash flows	$ 330.9	$ 0	$ 0	$ 0

Financial Instruments and Fai_4

Financial Instruments and Fair Value Measurements - Notional Amounts of Derivative Instruments (Details) - USD ($) $ in Millions	Sep. 30, 2022	Sep. 30, 2021
Foreign exchange contracts | Undesignated
Derivative [Line Items]
Notional amount	$ 5.1	$ 0

Financial Instruments and Fai_5

Financial Instruments and Fair Value Measurements - Additional Information (Details) - USD ($)	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Impairment charges	$ 58,900,000	$ 13,800,000	$ 0
Trade receivables	$ 22,200,000	$ 150,600,000
Customer Concentration Risk | Revenues | Three customers in aggregate
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Concentration risk percentage	40.10%
Customer Concentration Risk | Revenues | Two customers in aggregate
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Concentration risk percentage		30.70%	32.70%
Construction in progress
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Impairment charges		$ 13,800,000

Property, Plant and Equipment -

Property, Plant and Equipment - Components of Property, Plant and Equipment, Net (Details) - USD ($) $ in Millions	Sep. 30, 2022	Sep. 30, 2021
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 701.6	$ 891.6
Less: accumulated depreciation	(400)	(440.7)
Total Property, Plant and Equipment, Net	301.6	450.9
Land
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	1.4	3.5
Buildings
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	123.7	120.4
Machinery, equipment and fixtures
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	505.1	570.8
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	6.5	6.1
Construction in progress
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 64.9	$ 190.8

Property, Plant and Equipment_2

Property, Plant and Equipment - Additional Information (Details) - USD ($)	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Impairment charges	$ 58,900,000	$ 13,800,000	$ 0

Leases - Additional Information

Leases - Additional Information (Details) ft² in Thousands	12 Months Ended
	Sep. 30, 2022 USD ($) ft²	Sep. 30, 2021 USD ($)	Sep. 30, 2020 USD ($)	Apr. 01, 2022
Lessee, Lease, Description [Line Items]
Area of space leased (in square feet) | ft²	278
Term of finance lease	10 years
Finance lease renewal term	5 years
Right of use assets obtained in exchange for finance lease liabilities	$ 36,700,000	$ 0	$ 0
Right of use assets obtained in exchange for operating lease liabilities	$ 2,800,000	$ 0	$ 0
Term of contract for lease not yet commenced				10 years
Building lease, six year extension option
Lessee, Lease, Description [Line Items]
Extension term for lease not yet commenced				6 years
Building lease, four year extension option
Lessee, Lease, Description [Line Items]
Extension term for lease not yet commenced				4 years

Leases - Balance Sheet Informat

Leases - Balance Sheet Information (Details) - USD ($) $ in Millions	Sep. 30, 2022	Sep. 30, 2021
Finance Lease
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, Plant and Equipment, Net	Property, Plant and Equipment, Net
Total Finance Lease Assets	$ 35.5	$ 0
Current finance lease liabilities	3.6	0
Non Current Finance Lease Liabilities	32.6	0
Total Finance Lease Liabilities	$ 36.2	$ 0
Weighted-average remaining lease term (years)	14 years 6 months
Weighted-average discount rate	6.80%
Operating Leases
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Deferred Income Taxes and Other Assets	Deferred Income Taxes and Other Assets
Total Operating Lease Assets	$ 6.3	$ 3.9
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accrued expenses	Accrued expenses
Current operating lease liabilities	$ 2	$ 1.1
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Deferred Income Taxes and Other Liabilities	Deferred Income Taxes and Other Liabilities
Non Current operating lease liabilities	$ 4.3	$ 3
Total Operating Lease Liabilities	$ 6.3	$ 4.1
Weighted-average remaining lease term (years)	3 years 2 months 12 days	4 years 3 months 18 days
Weighted-average discount rate	5.90%	2.20%

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) - USD ($)	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Right of use assets obtained in exchange for lease liabilities
Financing Lease	$ 36,700,000	$ 0	$ 0
Operating Leases	$ 2,800,000	$ 0	$ 0

Leases - Maturities of Lease Li

Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Millions	Sep. 30, 2022	Sep. 30, 2021
Finance Leases
2023	$ 3.6
2024	3.6
2025	3.7
2026	3.7
2027	3.8
Thereafter	40.1
Total lease payments	58.5
Less: amount representing interest	22.3
Present value of lease liabilities	36.2	$ 0
Operating Leases
2023	2.3
2024	2.1
2025	1.2
2026	1
2027	0
Thereafter	0
Total lease payments	6.6
Less: amount representing interest	0.3
Present value of lease liabilities	6.3	$ 4.1
Total
2023	5.9
2024	5.7
2025	4.9
2026	4.7
2027	3.8
Thereafter	40.1
Total lease payments	65.1
Lessee, Operating Lease and Finance Lease, Liability, Undiscounted Excess Amount	22.6
Present value of lease liabilities	$ 42.5

Benefit Plans (Details)

Benefit Plans (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Defined Benefit Plan Disclosure [Line Items]
Benefit plan expense	$ 0.7	$ 3.6	$ 9	$ 9
Total employer contributions		$ 8.9
Maximum deferral percentage of base salary under deferred compensation plan		75%
Maximum deferral percentage of bonus and other eligible cash compensation under deferred compensation plan		100%
Amounts accrued under the Deferred Compensation Plan	3.7	$ 3.7
Swiss
Defined Benefit Plan Disclosure [Line Items]
Benefit plan expense	0.2
Unfunded net pension obligation	0.6	0.6
Plan assets	8	$ 8
Swiss | Other (income) expense, net
Defined Benefit Plan Disclosure [Line Items]
Benefit plan expense	$ 0.1

Supplemental Financial Inform_3

Supplemental Financial Information - Trade Receivables, Net (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning balance	$ (6.2)	$ (6.1)	$ (6.7)
Additions charged to costs and expenses	(18.4)	(16.3)	(16.3)
Deductions and other	23.2	16.2	16.9
Ending balance	(1.4)	(6.2)	(6.1)
Allowance for Doubtful Accounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning balance	(3.1)	(3.9)	(4.2)
Additions charged to costs and expenses	(0.3)	(0.3)	(1.1)
Deductions and other	2.1	1.1	1.4
Ending balance	(1.3)	(3.1)	(3.9)
Allowance for Cash Discounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning balance	(3.1)	(2.2)	(2.5)
Additions charged to costs and expenses	(18.1)	(16)	(15.2)
Deductions and other	21.1	15.1	15.5
Ending balance	$ (0.1)	$ (3.1)	$ (2.2)

Supplemental Financial Inform_4

Supplemental Financial Information - Long-Lived Assets (Details) - USD ($) $ in Millions	Sep. 30, 2022	Sep. 30, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 326.2	$ 484.8
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	109.3	165.6
Europe, Middle East, and Africa
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	174.5	258.7
Greater Asia
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	42.3	50.4
Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 0.1	$ 10.1